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Abstract Molecular imaging, Wrst developed to localise
antigens in light microscopy, now encompasses all imaging
modalities including those used in clinical care: optical
imaging, nuclear medical imaging, ultrasound imaging, CT,
MRI, and photoacoustic imaging. Molecular imaging
always requires accumulation of contrast agent in the target
site, often achieved most eYciently by steering nanoparti-
cles containing contrast agent into the target. This entails
accessing target molecules hidden behind tissue barriers,
necessitating the use of targeting groups. For imaging
modalities with low sensitivity, nanoparticles bearing
multiple contrast groups provide signal ampliWcation. The
same nanoparticles can in principle deliver both contrast
medium and drug, allowing monitoring of biodistribution
and therapeutic activity simultaneously (theranostics).
Nanoparticles with multiple bioadhesive sites for target
recognition and binding will be larger than 20 nm diameter.
They share functionalities with many subcellular organelles
(ribosomes, proteasomes, ion channels, and transport
vesicles) and are of similar sizes. The materials used to
synthesise nanoparticles include natural proteins and poly-
mers, artiWcial polymers, dendrimers, fullerenes and other
carbon-based structures, lipid–water micelles, viral capsids,
metals, metal oxides, and ceramics. Signal generators
incorporated into nanoparticles include iron oxide, gadolin-
ium, Xuorine, iodine, bismuth, radionuclides, quantum dots,
and metal nanoclusters. Diagnostic imaging applications,
now appearing, include sentinal node localisation and stem
cell tracking.
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Introduction
The introduction of laser illumination, scanning imaging,
digital detectors, computerisation, and time gating into light
microscopy in recent years has opened new vistas in analy-
sis of intracellular mechanics and tissue biology. Further
advances in resolution promise yet deeper insights as new
types of microscope evade the classical diVraction limits of
spatial resolution (Szellas and Hoppe 2007). However, at
the same time as light microscopical imaging is breaking
new ground, a new Weld of research has emerged, namely
molecular imaging. This encompasses advances in several
non-microscopical imaging modalities, some of which are
of Wrst-order clinical importance. The availability of new
hardware, together with advances in computer-supported
image processing, has facilitated advances in these forms of
imaging, just as in microscopy. The over-arching new Weld
of molecular imaging unites all the disparate imaging
modalities, including light microscopy, into a single
research area with shared aims and technical challenges.
The endeavour to visualise particular molecules within a
tissue can be traced back to the work of histologists such as
Feulgen (Benedum and Meusch 1999) developing speciWc
reagents for DNA, proteins (eosin), and carbohydrates
(PAS). Early workers used inorganic reagents and organic
dyes, many of them still in common use (Mulisch and Welsch
2008). The birth of molecular imaging dates to Coon’s use
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reagents, applying a targeting group (an antibody) to steer a
signal emitter (a Xuorochrome) into targets in tissues for
Xuorescence microscopy (Coons 1961). Today, the target-
ing group may be any of a range of molecules, including
antibodies and antibody fragments, nucleotides, and spe-
ciWc ligands, and the signal emitter can consist of a wide
range of materials according to the particular imaging
modality being applied, including organic Xuorochromes,
metals, metal oxides, and bubbles. The imaging systems
now include direct optical imaging using several regions of
the optical spectrum, and also indirect imaging in which
scanning systems are coupled with computerised calcula-
tion to derive images, including non-orthogonal and three-
dimensional images. Photons, ultrasound, and magnetic
Welds all are used to obtain images, which allow for
analysis of molecular interaction, for example, receptor
binding, or tissue tagging, for example, in malignant dis-
ease. Underlying this colourful variety of imaging systems
and new applications, there is a core of common technical
considerations, and of challenges to be solved. To over-
come a challenge in one type of imaging means an advance
in the whole Weld of molecular imaging, and technical solu-
tions developed in one imaging modality can be modiWed
slightly and applied to other types of imaging with relative
ease. It has become evident during recent years that several
of the challenges facing molecular imaging can be over-
come by use of nanostructured materials, and nanoparticles
now feature in all areas of molecular imaging. Molecular
imaging resembles the elephant in the Indian story, diYcult
to experience in its entirety and therefore reported by diVer-
ent authors in quite diVerent ways. To underscore the unity
of the Weld, we will therefore consider Wrst the various
imaging modalities, noting their common aspects but also
their particular characteristics. For the histologist, many of
the technical parameters are familiar in daily experience,
though in some imaging modalities they have quite
unexpected values. Other parameters are present in light
microscopy though rarely considered, yet stand in the
forefront of other imaging technologies. Before turning to
consider nanoparticles, we will review brieXy the various
types of imaging modality now in common (usually clinical)
use or presently undergoing development.
Light microscopy
Molecular Imaging is familiar to the histologist in the form
of immunohistochemistry and of in situ hybridisation,
which visualise certain speciWc types of molecule, but not
others, in the microscope. Even classical histochemical
stains achieve this; possibly, the most familiar form of
molecular imaging is haematoxylin and eosin (H&E),
which generates images distinguishing two major molecule
types. Some features of H&E in light microscopy represent
advanced molecular imaging in that it provides direct
multicolour imaging of two classes of molecule simulta-
neously by use of a single illumination source, with imme-
diate visualisation by eye. For these reasons amongst
others, it is the mainstay of clinical histopathology and the
source of most diVerential diagnoses guiding choice
between therapeutic options. It is therefore of prime clinical
importance, and sets standards for other imaging modali-
ties. Light microscopy oVers much more, however. Follow-
ing the introduction of antibodies as reagents by Coons,
immunohistochemistry was enriched by introduction of
indirect labelling, availability of monoclonal antibodies,
enzyme tracers, confocal scanning laser microscopy, two-
photon microscopy, and others. In the near future, antibody
fragments, generated both with and without the use of ani-
mal immunization, will further enhance this technique.
ImmunospeciWc labelling has been complemented by
nucleotide-speciWc labelling in the form of in situ hybrid-
isation to reveal genetic sequences in tissues. The genetic
modiWcation of certain proteins to allow them to be traced
in cells that express them represents a further form of light
microscopical molecular imaging. This area of work in
histochemistry is presently active and productive, as seen in
the continued development of new stains and methods for
visualising and evaluating them, often by close interaction
with quite diVerent disciplines, for example, the genetic
introduction of contrast groups into living animals (Lanman
et al. 2008; Livet et al. 2007). It has become possible to
view speciWc molecule types in living cells at high spatial
and temporal resolution (sub-micrometre, milliseconds),
and to track them for days, without signiWcant damage to
the cells. Accurate imaging of molecule types in tissue sec-
tions as thick as 50 m is possible, with sub-micrometre
resolutions. As required, light microscopical molecular
imaging can be complemented by electron microscopical
molecular imaging, which visualises multiple molecule
types simultaneously in single sections at better than 10 nm
resolution (Roth 1983).
Light microscopy oVers ideal conditions for molecular
imaging: in classical histology, the stain is applied to Wxed,
delipidated, and sectioned materials in which all structures
are cut through and sites to be contrasted lie open to the
stain. Light microscopy leads the molecular imaging Weld
in several respects, but it has a major limitation: the short
focal lengths of the microscope objectives prohibit use on
living subjects larger than about 1 mm in size. Also, unlike
the imaging modalities in clinical use, it tolerates the use of
toxic contrast agents and does not need to consider issues
related to pharmacokinetics.
Antibodies are not the only nanoparticles in use in light
and electron microscopy. Quantum dots have introduced
entirely new Welds of investigation, which could not be123
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and bleached, and had insuYcient quantum yields. Organic
Xuorochromes can be detected at approximately levels
down to 10¡8 moles.
Optical imaging
The near-infrared part of the optical spectrum is exploited in
light microscopy by use of Xuorochromes emitting at wave-
lengths up to about 700 nm. Microscope lenses are not
designed for use at much higher wavelengths than this.
However, camera lenses can be used throughout the near-
infrared spectrum, 600–900 nm, and this opens the imaging
modality known simply as “optical imaging” (see Fig. 1a).
The infrastructure required is particularly inexpensive: a
normal digital camera and a source of Wltered infrared light
are suYcient to produce good-quality images. The near-
infrared wavelengths between 600 and 900 nm provide a
near-transparency of living tissue. The cytochromes and
other pigments within the living cells cease to absorb at
wavelengths near and above 600 nm, and water molecules
only begin to absorb near and above 900 nm. However, the
transparency is not complete, and penetration of near-infra-
red light into the body is limited to a few centimetres.
Higher intensities above approximately 1,200 W/cm2 over-
heat the tissues, preventing deeper penetration by raising the
intensity of the light used. Thus, for clinical work, the pene-
tration depth limits the applicability of optical molecular
imaging. This is much to be regretted because this image
modality is patient-friendly. It is Wnding clinical use in local-
isation of sentinel nodes in large animals and potentially in
cancer patients, using picomolar amounts of quantum dots
and low light intensities, 5 mW/cm2 (Kim et al. 2003). For
biomedical research, the case is quite diVerent, because in
animals smaller than rabbits, the opacity of their tissues to
visible wavelengths does not prevent penetration of some
light to the centre of the animal. Irradiation of the animals
with blue light is therefore adequate to visualise green-Xuo-
rescing proteins within the animal’s internal organs. There-
fore, in mice, optical imaging is a popular approach to study
gene expression, protein expression, for example GFP, and
localisation of tumours by use of Xuorescent-labelled anti-
bodies. This renders the use of animal models as test beds in
optical imaging a useful means of developing nanoparticles
for use in other imaging modalities. A varied collection of
Xuorochromes has been used, including quantum dots (Bru-
chez et al. 1998; Chan and Nie 1998; Alivisatos 2004),
organic Xuorochromes, and colloidal metals.
Photoacoustic imaging
Photoacoustic imaging, sometimes also called optoacoustic
or thermoacoustic imaging, is a promising novel imaging
modality for non-invasive visualisation of semitransparent
objects, including soft biological tissue and biological sam-
ples (see Fig. 1b). It combines the advantages of optical and
ultrasound modalities. The principle of photoacoustics is as
follows. When short pulses of electromagnetic radiation,
such as light or radio waves, illuminate a semitransparent
object, a sound wave is induced at the point of interest deep
inside the sample via the thermoelastic eVect. In photoacou-
stic imaging, the goal is to recover the spatially varying dis-
tribution of the absorbed energy inside the illuminated
sample from the acoustic pressure measured outside the
sample. Structures of diVerent biological tissues reveal
highly varying optical absorption coeYcients, and thus,
photoacoustic imaging provides a good distinction between
malignant and healthy tissue, for example. Moreover, it is
expected to be useful in the early detection of cancer and
blood-rich lesions in vivo. It is also expected to provide
high resolution in microscopy. There are two major areas of
non-invasive in vitro and in vivo photoacoustic imaging,
the Wrst of which, “photoacoustic imaging”, applies unfo-
cused ultrasound. In real-time free hand photoacoustic
imaging, a part of the sample is visualised (Niederhauser
2004) and image reconstruction methods are necessary to
obtain the spatial information out of the measured data. In
full “photoacoustic tomography (PAT)”, either a complete
slice or the whole volume of the sample is reconstructed
(Kruger et al. 2002; Wang et al. 2003). In the literature,
several diVerent approaches to PAT imaging have been
proposed [see (Xu and Wang 2006) for an up-to-date sur-
vey on existing methods]. Current imaging systems provide
spatial resolution in the range of 100 m, and this is
expected to improve further in the future. The second tech-
nique is “photoacoustic microscopy (PAM)” (Zhang et al.
2006), which scans a focused ultrasound transducer along
the sample surface, and converts each received time-
resolved signal into a one-dimensional image along the
acoustic axis of the transducer; combining multiple images
acquired sequentially from various positions then produces
cross-sectional or three-dimensional images without use of
a reconstruction method as required in tomography. Driven
by potential medical applications, the area of photoacous-
tics is growing rapidly and steadily. Recently, there has
been considerable eVort to establish PAT as a tool in pre-
clinical research. Various groups have built small animal
imagers and have achieved promising results, for instance
imaging of the vasculature in the brain (Wang et al. 2003;
Kruger et al. 2003), and promising animal studies (Wang
et al. 2003, 2006; Zhang et al. 2006), and methods for
obtaining accurate, spatially resolved values of blood oxy-
genation (Laufer et al. 2005; Wang et al. 2006; Zhang et al.
2006). High-resolution photoacoustic imaging is ideally
useful for screening of biological samples in the range of
millimetres up to some centimetres, which makes it ideally123
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imaging. PAT imaging has also been used in connection
with high-intensity focused ultrasound to monitor tumour
treatment processes (Jin et al. 2005). Finally, photoacoustic
tomography complements existing imaging methods, and
fusion with CT, MRI, or ultrasound can provide signiWcant
additional diagnostic information (Niederhauser 2004).
X-ray imaging
Visualisation of the internal organs in living creatures Wrst
became a possibility in 1895, when Röntgen discovered
X-rays (Elke 1995). His Wrst image demonstrated the prin-
ciple of diVerential contrast available between bone, soft
tissues, and air-Wlled structures using radiography, and this
principle is followed until today (Seibert and Boone 2005).
Placing the animal between the X-ray source (about 30 kV)
and a detector casts a projected image onto the detector (see
Fig. 1c). This type of image has an inherent high spatial
resolution for high-contrast objects, but suVers from poor
contrast resolution. In principal, X-rays have the potential
to visualise subatomic structures, but the eVective resolu-
tion in vivo is limited by the hardware, object size, and
object geometry. Nonetheless, by use of Xatpanel detectors
or high-resolution Wlms and microfocus tubes, the objects
resolved are as small as 10 m, which is the highest resolu-
tion presently available for in vivo imaging of internal
organs of living animals. The infrastructure can be rela-
tively simple and inexpensive, and provides direct imaging
(no calculation is required). The monochrome images can
be viewed immediately on a monitor, with rapid adjustment
of image contrast and magniWcation. Contrast is generated
by absorption of the X-rays in the living tissues, and this
absorption is more eVective, the higher the atomic number
(n) of the absorptive elements involved. Usually calcium
(atomic number n = 20) in bones provides the contrast,
though barium (GI tract) and iodine compounds (i.v.
administration) are used (n = 56 and 53, respectively), and123
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contrast can also be introduced by introduction of air
(atomic numbers of nitrogen and oxygen are 8 and 7,
respectively, and the speciWc density of air is much lower
than that of the aqueous surrounding living tissues). The
metals used in dentistry (20–35% silver, with n = 47; tin,
with n = 50; »10% copper, with n = 29; »2% zinc, with
n = 30; 43–54% mercury, with n = 80) provide much
higher contrast. Molecular imaging by use of gold nanopar-
ticles (atomic number = 79) to generate localised contrast
in X-ray-projected images would therefore seem to be a
promising approach. This imaging modality exposes the
living subject to ionising radiation, which has additive
eVects and therefore can be applied as a diagnostic tool to
the same subject only until a certain safe dose has been
reached. However, diagnostic imaging operates at a dose
level, where radiation injuries are not encountered, even if
large numbers of exposures are taken.
PET/SPECT imaging
The possibilities of molecular imaging multiplied manyfold
with the advent of strongly emitting radioisotopes, giving
birth to nuclear medicine between 1930 and 1950 (Feld and
De Roo 2003). The imaging modality is positron emission
tomography (PET), using high-energy gamma rays generated
in a chain of nuclear radioactive reactions involving
production of positrons. The gamma rays have subatomic
resolution, though the eVective spatial resolution is limited
by the detector hardware and geometry to about 1 mm. In
PET, there is no external source of illumination (see
Fig. 1d). The radioactive tracer is injected into the living
subject and positrons are produced at the site of the disease
lesion, and their annihilation with electrons produces
gamma rays at that site; the subject is illuminated from
within the tissues. The gamma rays emitted from the disease
Fig. 1 Sketches illustrating the basic function of each imaging modal-
ity. In each case, the subject is a mouse bearing a tumour in one of its
internal organs. a Optical imaging: the sketch shows a conWguration,
which maximises optical penetration into tissues, with red light (e.g.,
from a light-emitting diode) causing Xuorescence of a targeted Xuoro-
chrome in the disease site, with detection of the Xuorescence by, for
example, a camera. This is the only imaging modality shown here,
which employs a lens to focus the image; the combination of mono-
chromatic light for excitation, and lens, Wlter, and camera to capture the
image, renders this imaging modality familiar to microscopists. For
small animals as shown here, the blue and green parts of the visible
spectrum can be employed instead of the red and near-infrared, but for
subjects larger than rabbits the red/near-infrared is necessary to pro-
vide better tissue penetration. The conWguration shown here generates
a projected image; by use of multi-angle exposures and scanning, fol-
lowed by reconstructive calculation, optical imaging can be used to ob-
tain three-dimensional images, but this is not essential in this imaging
modality. Optical imaging can detect targeted Xuorochromes injected
into the bloodstream (e.g., Xuorochrome-tagged immunoliposomes),
but can also detect cells, which have been genetically engineered to ex-
press Xuorescent proteins, in which case no injection is required just
prior to imaging. b Photoacoustic imaging: the conWguration shown in
this sketch uses one axis for illumination and a separate axis for detec-
tion of the ultrasound signal. ConWgurations with a single axis for both
illumination and also for ultrasound detection have been described.
The sketch omits the multi-angle multiple acquisition, the scanning
procedure, and the image reconstructive calculation that are necessary
(compare CT imaging below), to emphasise the basic principle of this
new imaging modality. Photoacoustic imaging does not always require
injection of a contrast medium, because haemoglobin generates strong
signals, allowing “native” imaging of blood vessels. If contrast in a le-
sion is required, this can be obtained by injection of targeted nanopar-
ticles. c X-ray imaging: conceptually, this is the simplest imaging
modality shown here. An X-ray beam illuminates the subject and dense
structures within the tissue cast shadows onto a detector (Wlm or a sol-
id-state detector), to form an image. The disease site in soft tissues will
not be visible in the image unless X-ray-dense materials have been
introduced into the lesion. Injection of a contrast medium, for example,
targeted metal nanoparticles, is therefore essential for acquisition of
contrast images. This modality has extremely high spatial resolution, is
readily available in the form of small machines in physicians’ oYces,
and is cheap to instal and simple to use. Images are available for view-
ing a few seconds after acquisition, which itself requires less than 1 s.
The image obtained is a direct projection—there is no reconstructive
calculation—and is therefore free of many types of artefact. d PET
imaging: amongst the imaging modalities shown here, this is the only
one, which requires no external “illumination” to generate an image.
The radionuclides are injected as “contrast agent” approximately 1 h
prior to imaging, and accumulate in the target. From this location, they
emit gamma rays, which are detected by specialised detectors. Multi-
angle multiple acquisitions in each image plane are necessary, indi-
cated in the sketch by arrows circling in the image plane. Multiple im-
age planes must be acquired by successive scanning of image planes
along the axis of the subject, as indicated in the illustration; the data is
processed by reconstructive calculation in a computer to generate im-
ages. To aid illustration, the image plane in the sketch is shown much
thicker than it actually is during real-life imaging. e CT imaging: this
version of X-ray imaging functions exactly as described above, but
with the addition of multi-angle multiple image acquisitions in the im-
age plane, indicated in the sketch by arrows circling in the image
plane. Data from multiple image planes must be acquired by scanning
along the axis of the subject, as indicated in the illustration, and com-
plex reconstructive calculations are then carried out by computer to
generate images in any desired plane through the subject, or to generate
three-dimensional images. The engineering required for this type of
image acquisition renders the equipment large, complex, and costly.
Acquisition of images requires many minutes; the radiation dose is
much higher than in direct X-ray imaging. However, this is the only
imaging modality, which can locate lesions in a human subject at much
better than sub-millimetre accuracy, and in three dimensions. f MR
imaging: the two external sources required for imaging, namely strong
magnetic Welds and high-frequency radio waves, are depicted here,
ignoring details of the geometric relationships. The signals emitted
from the subject are also in the form of radio waves, and are detected
by receive coils positioned around the subject. Multi-angle multiple
acquisitions are required in each imaging plane, as indicated in the
sketch by arrows circling in the image plane. Data from multiple image
planes are acquired by scanning along the axis of the subject, and the
data is processed by reconstructive calculation in a computer to gener-
ate images in any desired plane through the subject, or three-dimen-
sional images. Soft tissues are imaged with good contrast; so, injection
of a contrast medium is not always required. However, speciWc high-
contrast imaging of speciWc molecules requires injection of targeted
materials containing either iron oxides or a contrast agent such as gad-
olinium. As for CT and PET imaging, image acquisition times may be
major fractions of 1 h123
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surrounding the subject. As in CT, the various strengths and
origin of signal detected within the detector array are calcu-
lated by a computer to reconstruct the signal intensity at
each point in the common plane, and presented as a mono-
chrome image of that plane. By scanning along the living
subject, a series of image planes is reconstructed and fur-
ther calculation allows reconstruction of the image in any
desired plane through the subject. PET requires no signal
ampliWcation, because the gamma rays have energies in the
megavolt range; regarding contrast resolution, i.e.,
eYciency to detect minute concentrations of radionuclides
in tissue, PET is the most sensitive of all the imaging
modalities: the radionuclides deposited in the living subject
can be detected at amounts as low as 10¡11 moles, allowing
as few as a single cell to be detected by binding only two to
three labelled antibody molecules, e.g., somatostatin recep-
tors in neuro-endocrine tumours (de Herder et al. 2005).
Because of spatial resolution limitations, however, these
miniscule amounts of tracer cannot be localised within the
living subject to closer than approximately 2 mm. Thus,
PET suVers from a rather poor anatomical resolution. This
is overcome by hybrid imaging, in which PET is used to
track molecular events and high-resolution CT for localising
the events. Thanks to the extremely high sensitivity of PET,
the use of antibody molecules with single radionuclide
atoms attached is common. However, for multiple target-
ing, nanoparticles are being considered. This branch of
medicine already reaches “theranostics”, the combination
of diagnosis and therapy in a single structure (Boisseau
et al. 2006). PET however exposes the living tissue to
strongly ionising radiation, and due to the pharmacokinetics,
there is always a high radiation dose to the kidneys. This is
an extremely expensive imaging modality and requires an
extensive infrastructure. The imaging centre either requires
a nearby cyclotron to generate the positron-emitting radio-
nuclides, or it must have a reliable connection with a more
distant source—possibly a few hundred kilometres distant—
with excellent logistics to deliver the radionuclides to the
imaging centre with a time interval not longer than a few half-
lives. A radiochemical laboratory to handle the highly radio-
active isotopes is also an essential part of the infrastructure.
Computed tomography X-ray imaging
Although computed tomography X-ray imaging (CT)
employs X-rays for generating an image, this is a very diVer-
ent form of imaging from direct X-ray projection imaging
(see Fig. 1e). During image acquisition, the X-ray tube
rotates around the object. Transmission proWles are sampled
from up to 360 angles in digitized form using solid-state
detectors. Data is processed by dedicated computer hardware
using reconstruction algorithms to reconstruct the optical
densities at each point in the common imaging plane. This
reconstruction is presented as a cross-sectional image
providing superb contrast resolution and adequate spatial res-
olution. Volume scanning is achieved by moving the subject
continuously through the scanning beam; the volume data
set allows reconstruction of any desired plane through the
subject. The possibilities of acquiring contrasted molecular
images are the same as in direct projection X-ray imaging. In
CT, however, contrast molecules can be pinpointed in three
dimensions to millimetre accuracy. In addition, dual energy
imaging at diVerent kilovolt-settings allows high precision
quantiWcation of contrast materials, calcium and other radio-
opaque materials, as well as fat, for example, in fatty tissue or
the liver. Also, bone subtraction for demonstration of blood
vessels can easily be obtained. Dedicated animal/small
objects-imaging systems are available providing improved
spatial resolution for high-contrast objects. CT microscopy is
currently used for imaging the trabecular bone and neovascu-
larity. The disadvantage relative to direct projection X-ray
imaging is the proportionately higher dose of radiation to
which the subject is exposed. The considerably more expen-
sive equipment and infrastructure is available within all
major hospitals.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) (Lauterbur 1973;
MansWeld and Grannell 1973) applies a strong static mag-
netic Weld and a changing gradient magnetic Weld to the liv-
ing subject. In addition, the living subject is exposed to an
intermittent radiofrequency Weld. The MR signal arises
from within the body once the radiofrequency is turned oV.
For a strongly simpliWed illustration of these functional
principles, see Fig. 1f. The high-frequency radio waves
comprising the signal are received within the scanner and
decoded with respect to their spatial distribution (Callaghan
1991). As in CT, the imaging matrix consists of 512 £ 512
small elements (pixels, voxels) representing small tissue
samples within the imaging volume. Unlike ionising radia-
tion such as X-rays, MR imaging does not cause any poten-
tially harmful biological eVects. Gradient magnetic Welds
allow for imaging in any plane, even sampling an isotropic
3D-volume, which may be used to navigate in real time
through an organ or organ structures such as blood vessels.
The strength of the magnetic Weld is one factor determining
image resolution, and although images can be obtained
with Welds considerably lower than 1 T, most major clinics
work with high Weld strength machines, commonly 1.5 T,
though 3 T machines are gradually setting a new standard
(Tanenbaum 2006). Other factors contributing to spatial
and contrast resolution are the design of the imaging
sequence, sampling rate, and signal sampling. The mag-
netic Welds align atomic nuclei in the living subject and123
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ation” resulting in the emission of radio waves. Special
imaging sequences measure the radio waves from atomic
nuclei such as phosphorus, but usually waves from hydro-
gen nuclei (protons) are detected as signal. Thus, in vivo
monitoring of metabolism of high energy phosphorous
compounds is possible. Also, diVusion of water molecules
can be visualised and used for diagnostic purposes. The
detector (receive coil) is arranged close to and usually sur-
rounding the living subject, and the signals detected are
processed in a computer to reconstruct the signal strengths
arising from each image point (voxel) within the living sub-
ject; the resulting map of signal strengths within the imag-
ing plane is presented as an image of a section through the
subject. This imaging modality holds some surprises for the
histologist. For example, the signalling medium, high-fre-
quency radio waves, have a wavelength of approximately
7 m, related to the fashion in which they arise, by Lamor
precession of protons. The spatial resolution of the imaging
modality therefore does not depend on the wavelength of
the electromagnetic radiation used for the imaging. The
eVective spatial resolution is currently in the millimetre
range. High resolution imaging of small objects is possible
using dedicated MR-imagers with magnetic Weld strength
of 5–7.5 T. MRI is an extremely Xexible imaging modality.
The signals emitted by protons in water diVer from those
emitted by protons in lipids, and this is the source of much
of the image contrast in “native” images, some of the con-
trast arising from the paucity in some tissues such as bone.
By use of appropriate imaging sequences, the signals from
fats can be suppressed; so, the image becomes largely a
“water image”. In the presence of certain elements, gado-
linium being the one that is most commonly used, the sig-
nal strength obtained from protons is ampliWed strongly, so
that water at sites containing gadolinium emits much stron-
ger signals. Gadolinium compounds injected into the blood
therefore serve as contrast media, the blood emitting much
stronger signals than the surrounding gadolinium-free tis-
sues. The signals that are detected in MRI are relatively
weak, and even in the presence of gadolinium, the water
signal is not strong; the detection limit for gadolinium is
approximately 10¡5 moles/l (Runge and Wells 1995;
Shellock and Kanal 1999); this renders MRI relatively
insensitive, compared for example with the detection limit
of 10¡11 moles/l of PET/SPECT (Ter-Pogossian 1985)
or 10¡8 moles/l limit of Xuorescence detection in light
microscopy (Mason 1999). Partly, due to this relatively low
sensitivity, acquisition of a full series of images requires
many minutes or almost an hour. MRI does have another
type of detection based on local alterations induced in the
magnetic Weld by high susceptibility iron oxide particles,
this generating a signal suppression or void rather than a
positive signal (Weissleder et al. 1990; Nelson and Runge
1995), which results in a slightly better signal strength, with
a detection limit of approximately 10¡6 moles/l. MRI is
therefore a signalling modality, which can obtain signiWcant
beneWt by the signal ampliWcation, which can be obtained by
use of nanoparticles. Our own work (Paschkunova-Martic
et al. 2005) has demonstrated molecular imaging of the vas-
cular endothelial wall in the liver of mice by use of targeted
nanoparticles (Fig. 2). During the next years, the sensitivity
of MRI will be considerably enhanced, Wrst by use of new
technologies such as CEST (Zhang et al. 2008) and PARA-
CEST (Woods et al. 2006), using molecular complexes
whose chemical shifts generate oV-resonance contrast
through proton exchange, giving detection limits of
»10¡11 moles/l, comparable with PET/SPECT. Even
higher sensitivities would become available by abandoning
chemical shifts and using structured geometries to control
magnetic Welds within particles: lithographic and etching
techniques in micro-engineering can be used to fabricate
micro- and nano-structures with “tuned” geometries
capable of giving detection limits down to 10¡14 moles/l,
combined with spectral qualities providing MRI “in colour”
(Zabow et al. 2008); geometrical properties of the nanopar-
ticles here play an analogous role to exciton sizes of
quantum dots, which generate well-deWned colours. During
the next few years, MRI will reach detection limits much
lower than those now available by use of radio-isotopes,
without toxicity and without large changes required to
existing hardware. MRI is therefore a “space to watch” in
molecular imaging. To complete this introduction to MRI,
it should be noted that this imaging modality is associated
with high capital and infrastructure costs. MRI and PET
exhibit complementary imaging properties, and PET/MRI
fusion facilities have been built at many centres as back-to-
back radiology/nuclear medicine facilities. Most recently,
integrated single machines have been developed to
combine the high resolution of MRI with the high sensitiv-
ity of PET, but these are available only at a small number of
research centres across the world.
Ultrasound imaging
This imaging modality is relatively inexpensive and
requires relatively little infrastructure, and is also highly
patient-friendly. Soft tissues are largely transparent to ultra-
sound, but contain interfaces, which reXect ultrasound
waves diVerentially. These are ideal conditions for imaging
by use of ultrasound waves, and ultrasound imaging is a
well-established imaging modality in clinical use. Spatial
resolution depends on the wavelength used (currently in the
range of 5–15 MHz). The last three decades have seen
many proofs of the principle that molecular imaging can be
realised by use of microbubbles in ultrasound imaging
(Lindner 2002). However, nanoparticles have no role in123
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necessary to detect particles smaller than 1,000 nm diameter,
exceeding 30 MHz, do not penetrate more than a few milli-
metres into living tissues. Furthermore, contrast media are
based on air–liquid interfaces of high curvature (bubbles),
and creating bubbles of nanosize is a diYcult undertaking.
For the foreseeable future, ultrasound molecular imaging
will be carried out by use of microparticles (microbubbles,
with diameters generally larger than about 5 m). We
mention this imaging modality for the sake of complete-
ness, but it falls outside the scope of this review to provide
a more detailed description. Ultrasound can however be
generated by optical stimulation of structures within a
living tissue, and nanoparticles can play important roles in
“photo-acoustic imaging”, as described above.
Why nanoparticles?
Stationary accumulation of signalling groups at speciWc tar-
get sites
Molecular imaging reveals the location of particular molec-
ular types within a tissue. To obtain adequate contrast in the
image, signal-emitting materials must be accumulated in a
stationary fashion at the site of the molecules. Radionuclides
emit energetic signals, which provide high signal-to-noise
ratios, so that attachment of a single radionuclide atom to a
targeting molecule (such as antibody) allows stationary
small accumulation of such molecules within a tissue to
be imaged with high contrast. The accumulation of
10¡11 moles of such gamma-emitting conjugates is ade-
quate for imaging (see above). Fluorochromes emit signals
approximately one thousand times weaker, so that a Xuores-
cence image of comparable quality would require accumu-
lation of 1,000 times more Xuorochrome molecules at the
site than for PET. The number of the speciWc target mole-
cules at the site may not be suYcient to allow stationary
accumulation of so many antibody molecules, and in this
case the use of antibody molecules conjugated to a few
hundred Xuorochromes would be needed. A single antibody
molecule will not carry more than a dozen Xuorochrome
molecules without loss of its speciWc binding, rendering use
of a particulate matrix essential to carry the payload of a
few hundred Xuorochromes. Gadolinium chelates in water
emit signals yet one thousand times weaker than Xuoro-
chromes, and in this case the use of particulate matrices
becomes mandatory for successful imaging; the particles
Fig. 2 In this previously published image (Paschkunova-Martic et al.
2005), we showed that latex nanoparticles bearing gadolinium-DTPA
chelates as signalling groups, and tomato lectin molecules as targeting
groups, adhered strongly to the vascular wall in the liver of living mice.
This series of MRI images presents a time-series, beginning with time
zero (t = 0 min), an image acquired before injection of nanoparticles,
and passing through 39 min at which time the blood of the mouse con-
tains high concentrations of nanoparticles generating strong contrast in
the blood space of the liver vessels. Fifty-Wve minutes after injection of
the nanoparticles, a rinse with 1.0 ml of buVer failed to clear the nano-
particles from the blood vessels. At 71 min, we rinsed the circulatory
system of the animal with 4 ml buVer, which is double the blood
volume of the mouse, which Xushed the blood space but left nanopar-
ticles embedded in the vascular walls and these therefore appear white
in the image. The resolution in these images is better than 0.1 mm in
the image plane; the MRI machine was operated with a magnetic Weld
of 1.5 T (machine normally in routine clinical use). The lower series of
images shows that gadolinium–DTPA chelates (Magnevist®) at 10 min
after intravenous injection are already concentrated in the kidney, and
at 18 min are essentially in the urinary bladder. These images demon-
strate the high spatial resolution of MRI, and also the use of nanopar-
ticles to prolong circulation time and to allow targeting to a speciWc
tissue site. All calibration bars 1 cm123
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ies) and bear a payload of several thousand gadolinium che-
lates. The contributory eVects of voxel size are ignored in
this discussion. As discussed below, optimised particles for
most applications will be at least 20 nm diameter and possi-
bly as large as 300 nm, and will therefore fall under the
deWnition of nanoparticles.
Occasionally, nanoparticles are not needed. For some
applications, larger particles are better. An example is cell
tracking by MRI. For cell tracking in vivo, MRI is the ideal
imaging modality. It tracks cells throughout the entire vol-
ume of the animal, even of large laboratory animals; it has
excellent soft tissue contrast, acceptable spatial resolution,
and is biologically safe and uses non-ionising radiation.
Tracking the migration of small numbers of cells is
required for analysing cancer cell metastasis and in studies
of transplantation, including tracking of stem cells. By use
of optimised radio-frequency coils, specialised magnetic
gradients (Heyn et al. 2006), long scan times (2 h), and high
magnetic Welds [Hoehn et al. (2002): 7 T; Kircher et al.
(2003): 8.5 T], adequate signal-to-noise ratios can be
obtained, allowing detection of approximately single cells
loaded with nanoparticulate iron oxides (ultra-small parti-
cles of iron oxide, “USPIOs”, 30 nm diameter); indeed, sin-
gle cells can even be detected by use of a 1.5 T clinical
scanner (Foster-Gareau et al. 2003). A signiWcant advance
was the realisation (Engberink et al. 2007) that the iron
oxide particles loaded into the cells need not be nanoparti-
cles (Benderbous et al. 1996; Wang et al. 2001; Jung 1995)
but that better results could be obtained with larger nano-
particles (small particles of iron oxide, “SPIOs”, 150 nm
diameter) (Zelivyanskaya et al. 2003; Sipe et al. 1999;
Metz et al. 2004), and that excellent results can be obtained
by loading the cells with micrometre-sized iron oxide parti-
cles (micro-particles of iron oxide, “MPIOs”) (Shapiro
et al. 2005; Hinds et al. 2003; Wu et al. 2006). A basic
problem of iron particles is that they cause a signal void
(negative contrast), which is diYcult to quantify. Thus, iron
particles can only be detected eYciently if they are sur-
rounded by tissue, which acts as a signal intense back-
ground.
At the other extreme, there are occasional cases involv-
ing extremely dense accumulations of target molecules
(Artemov et al. 2003), allowing successful MR imaging by
use of only few gadolinium chelates bound to each anti-
body molecule; in these cases, (nano)particulate carriers are
not necessary. The general case, however, is that a signal
ampliWcation will be required. It is possible to use a wide
range of elements for contrast generation in MRI, though
all have lower relaxivities than gadolinium and would thus
require more atoms per nanoparticle for imaging than does
gadolinium; Xuorine has been frequently used (Lanza et al.
2005).
How do nanoparticles amplify signals?
The signal generators are localised to the nanoparticles in
stable fashion, for example, by covalent binding. Figure 3
shows the principle of a multifunctional nanoparticle,
which serves as drug carrier, is targeted, and is decorated at
its surface with numerous tightly bound gadolinium che-
lates to serve as signal generators. The signal emitted by
Fig. 3 a Small molecular weight drug: the drug molecule (3-amino-1-
hydroxypropylidene)bis-phosphonate (Pamidronate) is sketched as a
particle of approximately 2 nm diameter, the size of many small drug
molecules. At the right hand side, the pamidronate particle is shrunken
to approximately the size it will occupy in (b). b Drug-bearing nano-
particle: a 25 nm diameter nanoparticle can enclose approximately
1,000 pamidronate molecules. Pale blue shading represents the matrix
of the nanoparticle, which must be crosslinked for stability. At the right
hand side, an antibody molecule, shown to scale, is attached to the
nanoparticle to serve as targeting group; the linker mediating the
attachment is not shown in this sketch. Around its surface, the nanopar-
ticle is decorated with gadolinium chelates, represented here as “Gd”
and approximately to scale; the linker connecting the chelate to the
nanoparticle surface is not shown. The surface of the 30 nm diameter
nanoparticle has adequate space for approximately 1,000 Gd chelates.
This sketch represents an idealised multifunctional nanoparticle, serv-
ing as carrier for a drug, with a targeting function and with suYcient
signal generators to provide strong signalling in MRI. The particle
could be a liposome, a dendrimer, a protein particle, or one of several
other particle types; the signal generator need not be gadolinium; it
could be a Xuorochrome or a radionuclide; there need be no drug at all,
or pamidronate could be replaced by any of numerous other drugs123
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generated from the surrounding aqueous medium is close to
zero; the nanoparticle has a strong signal-to-noise relation-
ship. At the target site, there will accumulate many thou-
sands of such nanoparticles as this, and will generate
thousands of signals for each of the target molecules to
which they are bound: this thousand-fold ampliWcation
arises from the small volume of the target site, and from
nowhere else. In MRI, the accumulated nanoparticles must
Wll a considerable part of the tissue volume represented by a
voxel; otherwise, the signal will be averaged out in the
voxel and will not be detectable; the total gadolinium
within the voxel must be close to 1 mM for reliable detec-
tion of the signal. In this way, the nanoparticles act like a
histochemical stain, which accumulates at certain sites in
the tissue and provides colour or contrast at those sites, and
is absent elsewhere.
Particulate carriers for molecular imaging will almost 
always be nanoparticles
Each functionality associated with a structure requires a
certain volume of space, and a collection of functionalities
needs a certain ordered spatial arrangement. An example is
the human head, with its functionalities of vision, audition,
olfaction, mastication, and cerebration, and which is
between 20 and 30 cm tall. The same functionalities can be
found in the smallest of the apes, a certain tarsir, with a
head only 1.5 cm tall. It is quite likely that this is the small-
est head capable of accommodating these particular func-
tionalities. For molecular imaging, a particle requires a
recognition and adhesive functionality, a signalling func-
tionality, and a carrier functionality, as discussed earlier.
These functionalities require protuberances, branches,
hinges, sculpted surfaces, and other spatial specialisations,
and each of these in turn must be constructed of a few hun-
dred atoms. The immunoglobulin molecule with its two
recognition sites has a gyration radius of 6 nm, and a third
functionality in the Fc region (activation of other immune
functions) requires further several nanometres, so that the
entire molecule is approximately 12 nm in diameter. The
ribosome, with its several recognition sites and several
eVector sites, is 20–25 nm in size. The several functional-
ities required in a particle that should carry a few thousand
gadolinium chelates, and also bear several targeting groups
(such as antibody molecules), will require a volume not
much less than a ribosome. It is safe to assert that such a
particle will not be feasible below a size of approximately
20 nm. It will be a small nanoparticle, and any further addi-
tion to its functions will render it larger. It does seem that a
large number of functionalities, and also a large molecular
payload, will Wt into a nanoparticle 50 nm in size, which in
turn will Wt into an endocytotic vesicle. Viruses, which
accommodate most of the functionalities required for tar-
geted drug delivery, are frequently in this size range and
not smaller.
Theranostics requires multifunctional nanoparticles
There are reasons to expect that MRI will become much
more sensitive in the next few years (see below). As its sen-
sitivity approaches and perhaps exceeds that of Xuoro-
chromes, the need for nanoparticles in MRI molecular
imaging might seem to fade away. However, there is a sep-
arate reason why nanoparticles will be required even in
more sensitive versions of MRI, and this is theranostics.
The payload of the nanoparticle can consist of drug mole-
cules and of signalling materials. This combination allows
the nanoparticle to be located within the living subject and
at the same time to release drugs into a target site, enabling
molecular imaging to be combined with therapy. This
“therapy” plus “diagnostics”, or “theranostics” holds the
promise in future of monitoring the eVectiveness of therapy
simultaneously with delivering the therapy, and thus of tai-
loring the therapy to the individual needs of a patient (“per-
sonalised medicine”). The design of a multifunctional
theranostic nanoparticle is a large challenge, but it is evi-
dent that such multifunctional particles can be created suc-
cessfully, because viral particles are exactly such particles.
Design principles of nanoparticles for molecular 
imaging
Size of nanoparticle
As discussed earlier, multifunctional nanoparticles will
exceed 20–30 nm in size. In this size range, nanoparticles
are easily taken up into cells via endocytotic vesicles,
which typically are 40–60 nm diameter. Nanoparticles
larger than 150 nm will not enter the cells by endocytosis
and will be at the upper limit for passage through caveolae;
they will be phagocytosed by macrophages and therefore
routed via the reticulo-endothelial system to lymph nodes
and the spleen. These considerations suggest a size between
30 and 150 nm diameter for nanoparticles to be used in
molecular imaging, and this size also permits drug payloads
of several tens of thousands of drug molecules within each
nanoparticle.
Number of targeting groups
In immunohistochemistry, an antibody molecule binds
speciWcally to its antigen within a tissue section, thus
targeting itself, plus a payload consisting of a peroxidase
enzyme molecule, into a speciWc antigenic site. The anti-123
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with a mass not exceeding 300 kDa. A nanoparticle of
50 nm diameter is much heavier, with a mass close to
40 MDa if it consists of a polymer matrix. A single anti-
body molecule attached to such a nanoparticle may not
develop suYcient binding force to anchor the large mass
to a target antigenic site. Furthermore, in immunohisto-
chemistry, the antibody–enzyme complex is applied in a
non-turbulent environment and incubated for long periods
of many minutes to facilitate adhesion to its target anti-
gen. In the bloodstream of a living animal, the environ-
ment is turbulent and an antibody-targeted nanoparticle
may come into close contact with a target molecule for
only a few seconds: a bond formed between the antibody
and its antigen may not be strong enough to halt the
motion of the nanoparticle and to anchor it to that speciWc
site. To multiply the adhesive power of the nanoparticle, it
is necessary to attach many antibody molecules to it,
which by binding to the antigen in rapid succession will
slow down the moving nanoparticle and eventually anchor
it to that site. As a result, the targeted nanoparticle will
roll along its targeted surface, in a fashion comparable to
leucocytes rolling on an endothelial surface at the initia-
tion of the inXammatory process; this comparison is not
perfect, because the leucocyte weighs [(8,000)3 nm/
(25)3 nm] 30 million times more than the nanoparticle and
binds via the attachment of billions of speciWc adhesion
molecules. A more exact comparison is with the natural
targeted nanoparticles, the viruses. A T4 bacteriophage is
about 30 nm in size and adheres via six “legs” to its target,
each leg bearing an adhesive site at its “foot”. The wild-
type HIV viral particle, about 130 nm is diameter, bears
14 targeting spikes, which is about one spike per
3,000 nm2 of surface area. Following the natural example,
a designer of artiWcial nanoparticles might plan to attach
ten antibody molecules to the 50 nm nanoparticle (one
antibody molecule per 250 nm2 of surface area) to ensure
its stable anchorage at the target site. Since antibodies are
expensive, natural selection amongst nanoparticle design-
ers will ultimately help determine the minimum number
of antibody molecules necessary to tether a nanoparticle
to its antigenic site.
Number of signalling groups
In diVerent imaging modalities, one signalling group per
particle may be enough, although that signalling group
functions in quite diVerent ways in the diVerent modalities.
In PET, one or two radionuclide atoms per particle are ade-
quate for strong signalling. In Xuorescence microscopy, the
nanoparticles, known as quantum dots, each contain one
exciton. In MRI, SPIOs are 150 nm nanoparticles consist-
ing of a single signalling group. In photo-acoustic imaging,
a single metal nanoparticle suYces to generate the neces-
sary signal. However, in the case of organic Xuorochromes
or of gadolinium-contrasted MRI, numerous signalling
groups are attached to each nanoparticle. As described
above, the required number is related to the sensitivity of
the detection in any given modality. For Xuorochromes, a
few hundred per particle is adequate, but for MRI the parti-
cle should carry a few thousand gadolinium chelates (Gd
chelates). Since gadolinium-enhanced contrast requires free
diVusion of protons, the particles must be water-permeable
if they contain Gd chelates distributed throughout their
volume.
Mechanical properties
For survival within the turbulent dynamics of the blood-
stream, a nanoparticle requires a certain mechanical integrity.
Nanoparticles held together only by charge-based forces
will certainly be disrupted rapidly. Crosslinking by cova-
lent bonds lends the necessary stiVness and cohesion to
survive bloodstream turbulence, and also guarantees the
stability of the nanoparticle at the target site, where sta-
tionary accumulation of stable nanoparticles is essential
for molecular imaging. However, a nanoparticle can be so
stable that its clearance from the organism is possible
only by macrophages, which prolongs the duration of
exposure to any toxins (such as gadolinium) that are pres-
ent in the nanoparticle. An ideal signalling nanoparticle
would remain intact at the target site (and nowhere else)
until its molecular imaging role is fulWlled, then disinte-
grate rapidly and vanish from the organism within hours,
for example, by renal excretion; such nanoparticles are
not available yet.
Surface decoration
Nanoparticles of any size are foreign bodies in the blood,
and therefore liable to clearance via macrophages and the
reticulo-endothelial system. The larger the particle, the
more likely this will be, but all nanoparticles require an
ability to evade the immune system. To evade uptake by
macrophages, they may be decorated with small polymers
of polyethylene glycol (“PEGylated”), lending them the
characteristic known colourfully in the literature as
“stealth” (Moghimi et al. 2001; Moghimi and Szebeni
2003).
It is evident that the design and construction of a
nanoparticle satisfactory in all the above respects is a
major task in several Welds of chemistry, and requires
detailed knowledge of the working environment, the
organism, in which the nanoparticle must eventually
mediate molecular imaging. This review returns to these
matters below.123
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The nanoparticle matrix
Liposomes
Liposomes are the most mature form of nanoparticles
(Mulder et al. 2005); development of these began in the
1970s (review by Drummond et al. 1999). They consist of
amphiphilic compounds (phospholipids, glycolipids, and
aminolipids) formed into membranes (Hofheinz et al.
2003), enclosing aqueous cavities (Fig. 4). Some are
approved for clinical use, including PEG and non-PEG
liposomal doxorubicin for metastatic breast cancer, and
PEG liposomal doxorubicin and liposomal daunorubicin
for Kaposi sarcomas (see Hofheinz et al. 2003). Liposomal
nanoparticles are popular substrates for use in development
of targeted nanoparticle systems, for example, as immuno-
liposomes targeted by antibodies or antibody fragments.
Metal oxides
Metal oxides are long-established substrates for nanoparti-
cle production (Weissleder et al. 1990). Superparamagnetic
iron oxide (SPIO) nanoparticles exhibit extremely high
relaxivity. Such a particle consists of magnetite core sur-
rounded by a matrix material such as dextran (Fig. 4). The
distortion, which the core causes in the magnetic Weld,
leads to hypo-intensities in T2- or T2*-weighted images, the
image areas containing SPIOs therefore showing low signal
intensity (“negative contrast”). The signal void due to the
large magnetic susceptibility of a SPIO is much larger than
the particle size, enhancing detectability. In addition to uses
in molecular imaging, involving attachment of targeting
groups to the SPIOs, these particles have been used to track
numerous cell types (Dodd et al. 1999; Cunningham et al.
2005), including T lymphocytes (Kircher et al. 2003),
macrophages (Engberink et al. 2007), and stem cells
(Frangioni and Hajjar 2004; Partlow et al. 2007). Although
there are claims of detection at 10¡12 M (Gao and
Hillebrenner 2008), present-day technologies involve a
trade-oV between the SPIO imaging parameters including
Weld strength, gradient characteristics, acquisition time
(Kircher et al. 2003; Heyn et al. 2006) against the number
of cells to be detected. Also there are diVerences in
detection sensitivities between SPIOs and the ultrasmall
SPIOs (USPIOs) (Engberink et al. 2007). Nano- and micro-
particles in the form of iron oxide particles are available
commercially in streptavidin-conjugated form and can be
used to target tumour cells (Artemov et al. 2003). The
conjugation of drugs to the surface of iron oxide nanoparti-
cles has been reported (Hung et al. 1990), but as with the
metal nanoparticles, large amounts of drugs cannot be
Fig. 4 Three forms of nanoparticles are sketched and one form is
shown as an electron micrograph. The simplest form of liposome con-
sists of a micelle with hydrophoblic lipid components at the surface,
and hydrophilic chains projecting into the water-Wlled internal cavity.
A liposome of this size can already carry hundreds of small drug mol-
ecules, either within the water-Wlled cavity or within the lipid shell, or
aligned between the water- and lipid-environments. Typically, lipo-
somes are PEGylated at their outer surfaces, and targeting groups such
as antibodies, aptamers, or peptides can be attached (not shown). Lip-
osomes can be constructed in much more complex versions, for exam-
ple, as multilamellate bodies, which are considerably larger:
liposomes larger than 200 nm diameter are often reported. An ultra-
small particle of iron oxide (USPIO) is sketched: the iron oxide parti-
cle (brown) is 4–6 nm diameter and is derivatised with polymer chains
(green); dextran is frequently used for this, chitosan is another of the
numerous alternatives. To these chains can be attached targeting
groups (not shown). A protein-based (albumin) nanoparticle pre-
pared in our laboratory is shown as an electron micrograph. The Epon-
embedded particle was imaged non-osmiWed, and the greyscales as-
signed false colours. The amorphous protein structure, shown red, en-
closes numerous water-Wlled internal cavities (green), which provide
pathways for molecule exchange, for example, of any drugs that the
albumin could be transporting. A quantum dot is sketched. The central
semiconductor crystal (green), about 5 nm diameter, is coated with
several layers (shades of orange and yellow), which may include sil-
ica, proteins, and peptides, and which protect the crystal from the sur-
rounding aqueous environment. They also provide attachment sites
for targeting groups. The precise diameter of the crystal determines
the colour of the light it emits. The dot shown here is simple, but more
complex core/shell arrangements of two crystal types are used to pro-
duce dots with emissions at longer wavelengths, for example, in the
infrared123
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based on metals other than iron have been used to perform
vaccination, based on oligopeptides attached to any of the
range of metal oxide nanoparticles, including the particles
(Frey et al. 1997, 1998).
Dendrimers
Dendrimers are built up as molecules from small subunits
attached to one another in successive stages or generations,
leading to extremely large structures of nanoparticle size
(Kobayashi et al. 2005; Bulte et al. 2001). As substrates for
nanoparticle production, they have several advantages,
including the high level of control over architectural design
and molecular weight, chemical composition, size, shape,
branching length/density, and surface functionality. Simpli-
Wcation of their synthesis, by the “lego” and “click”
approaches, has reduced their costs of production (Svenson
and Tomalia 2005). Control over their size and composition
allows predictable tuning of their biocompatibility and
pharmacokinetics (Lee et al. 2005). They have been used in
imaging of lymph nodes in cancer (Kobayashi et al. 2005)
and to track stem cells (Bulte et al. 2001), but these applica-
tions were not targeted and represent precursor develop-
ments for molecular imaging.
Polymers
Polymers are a further popular substrate for creation of
nanoparticles. Much research has aimed to conjugate drugs
into polymers, producing copolymers such as the N-(2-
hydroxypropyl)methacrylamide (HPMA)–doxorubicin
conjugate PK1 (Vasey et al. 1999), and other HPMA–
copolymer conjugates, some useful in imaging (Duncan
2005). Polyglutamic acid (PGA)–paclitaxel copolymer
(CT-2103) (Xyotax) is entering the market as cancer treat-
ment for non-small-cell lung cancer in women (Singer
2005). Polyethyleneglycol in conjugation with camptothe-
cin (EZ-246, Pegamotecan) (Posey et al. 2005) and cyclo-
dextrin in conjugation with camptothecin (Schluep et al.
2006a, b; Zamboni et al. 2006) are entering clinical trials.
Polymer–drug conjugates are being directed not only
against tumour cells, but also against angiogenic blood ves-
sels, for example, HPMA–fumagillol (TNP-470) caplosta-
tin (Satchi-Fainaro et al. 2004; Huang et al. 2004; Inoue
et al. 2003; Bhujwalla et al. 2003), the HPMA copolymer–
RGD4C-Tc-99m conjugate, capable of targeting tumour
angiogenic vessels and delivering adequate radiotherapy to
arrest tumour growth (Mitra et al. 2006) and PEGylated
cyclic arginine–glycine–aspartic acid (RGD) radiotracers
(64-Cu-DOTAPEG-RGD and 125 I-RGD-mPEG) targeted
at integrins (Chen et al. 2004a, b). The emphasis in work on
polymer–drug copolymers lies at present on drug delivery,
but attachment of signal generators to these copolymeric
nanoparticles is of considerable interest, because this would
allow real-time monitoring of drug biodistribution and
action. For reviews of this active Weld, see Duncan (2005)
and Vicent (2007). Carbohydrate polymers such as chitosan
(Agnihotri et al. 2004) and dextran (Dhaneshwar et al.
2006) have been used to enhance the solubility, lymphatic
uptake, and physiological acceptance of both enzymes and
drugs. Latex polymer nanoparticles have been used to
demonstrate the vascular wall by molecular imaging
(Paschkunova-Martic et al. 2005).
Proteins
Proteins are further major matrices for nanoparticles. Albu-
min, as the body’s major transporter molecule, is being
formed into nanoparticles (Fig. 4), incorporating several
major types of drug, for which it improves biocompatibil-
ity, bioavailability, and safety (see below). Gelatin nano-
particles are also under investigation (Balthasar et al. 2005;
Wartlick et al. 2004), building on the long series of investi-
gations that have been carried out into controlled release
from this protein. Natural protein complexes or “protein
cages” have also been employed (Flenniken et al. 2006).
Quantum dots
Quantum dots are semiconductor materials prepared in
nanoparticle form (Fig. 4), varying in size slightly to tune
their emission wavelengths to diVerent values (Bakalova
et al. 2007). They exploit a quantum eVect related to parti-
cle size, which retains incoming energy inside the particle
in the form of “excitons”. The energy of the exciton is
determined by its wavelength and this, in turn, is con-
strained by the size of the particle. When the energy of the
exciton is emitted from the particle, it appears as a photon
of precisely deWned wavelength, so that quantum dots
generate extremely pure monochromatic emitted light
(Fig. 5a). They also do this with extremely high quantum
eYciencies, which can exceed 60%. For these reasons, they
provide powerful emission for use in Xuorescence micros-
copy, and since the emission depends on physical parame-
ters of the quantum dots, it is stable: it does not bleach
(though the dots may blink), and does not depend on envi-
ronmental parameters such as pH value. They are available
commercially in a range of pure colours, and since quantum
dots do not have absorption maxima but rather can be
excited by use of a range of wavelengths, all the colours
can be visualised simultaneously by use of a single light
source. They provide excellent substrates for optical imag-
ing of tumours (Gao et al. 2004; Wu et al. 2003; Lidke et al.
2004; Lee et al. 2008) and can be coated with amphiphilic
block copolymers with drug delivery functionalities (Gao123
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containing frequently toxic cores (Fig. 5b), which may be
exposed by oxidative, photolytic, and mechanical instabili-
ties (Hardman 2006). They are thus intrinsically unsuited to
targeted drug delivery, because any dissolution of the outer
shell (in which the drug must be loaded) exposes the toxin
core, but have important applications in histopathological
diagnostics (Xing et al. 2007).
Metals
Gold nanoparticles oVer considerable advantages in
terms of standardisation and toxicological properties.
They are excellent substrates for optical imaging (Chen
et al. 2005; Elghanian et al. 1997) and photoacoustic
imaging (Copland et al. 2004). They have been used for
true molecular imaging based on attachments of
aptamers to visualise cancer cells (Huang et al. 2008a).
Silver nanoparticles also exhibit extremely interesting
optical properties (Haes and Van Duyne 2002) and can
be considered for targeted molecular imaging. Bismuth
nanoparticles have been developed for use in X-ray CT
imaging (Rabin et al. 2006), and like gold nanoparticles,
might be considered for use in targeted molecular
imaging.
Viruses
Viruses and their capsides oVer potentially highly diVeren-
tiated nanoparticles for attachment of speciWc targeting
groups and may have an important role in future molecular
imaging (Allen et al. 2005; Lewis et al. 2006).
Fig. 5 a The physical size of the 
crystal cores, which lie at the 
heart of quantum dots, is the 
parameter, which determines the 
energy of the exciton contained 
within the dot, and therefore the 
pure colour of the light, which 
the dot emits. Since the light 
emitted when an exciton gives 
up its energy is monochromatic, 
the dispersity of the colour emit-
ted depends upon the size disper-
sity of the dots. Commercial dots 
are almost monodisperse, allow-
ing several colours to be emitted 
within the visible spectrum, 
from dots with cores of 2.0–
5.0 nm. b The chemistry of 
quantum dots couples together 
elements from Groups II/VI, IV/
VI, and III/V of the Periodic Ta-
ble, as shown here connected by 
lines. The radioactive members 
(lightning symbol) of the groups 
are not employed. However, the 
majority of combinations used to 
create quantum dots contain at 
least one toxic partner (danger 
symbol), and several consist of 
two toxic elements123
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Carbon-based nanoparticles such as fullerenes (Bosi et al.
2003; Fatouros et al. 2006; Oberdörster 2004) and nano-
tubes (Gao and Hillebrenner 2008; Pagona and Tagmatar-
chis 2006) are under development as contrast agents that
can easily be decorated with targeting groups, but exhibit
some unfavourable toxicological properties, especially the
nanotubes.
All the various material versions of nanoparticles share
the advantages of nanosize, but their suitabilities for diVer-
ent applications depend on their chemistries and pharmaco-
logical tolerance. Matching nanoparticle types to clinical
applications depends on the core chemistry, but also on the
capacity for multiple functionalisation, standardisation,
adjustment of particle stability, and expense of compo-
nents. Targeting groups attached to the nanoparticles can
include antibodies or antibody fragments, peptides, apta-
mers, and nucleotides. Smaller groups such as peptides
oVer design advantages. The types of linkers presently in
use, generally maleimide, biotinylation, carbodiimide, are
not optimal and new possibilities are being explored. Sig-
nalling groups include gadolinium, Xuorine, or iron oxides
for MRI and gold clusters or organic Xuorochromes for
optical imaging. Particularly interesting are “molecular
beacons”, which emit signals only after interacting with a
target (Massoud and Gambhir 2003), considerably enhanc-
ing contrast.
The targeting groups
In molecular imaging, the targeting groups play the cen-
tral role of mediating adhesion to the target sites. To do
this reliably, they should exhibit exquisite speciWcity and
high aYnity binding at the targets. The major types of tar-
geting groups presently in use are antibodies and their
derivatives, oligonucleotides in the form of aptamers, and
speciWc ligands. Much of the development work is condi-
tioned by two factors, namely immunogenicity and the
capacity of the targeting groups to access all the targets
present in the organism. Both these factors are exempli-
Wed well in the history of antibody molecules and their
derivatives.
Antibody molecules
Antibodies, long used in immunohistochemistry, are ideal
targeting agents. This was foreseen by Ehrlich (1900), who
forecast that they would serve as “magic bullets”, a prom-
ise only now being realised, 100 years later. They combine
speciWc recognition of epitopes with high aYnity binding
to them. Antibody molecules have undergone extensive
development by genetic engineering since 1985, and the
reagents derived from them, the novel possibilities of gen-
erating human antibodies and antibody fragments without
humans, and of generating entirely new and clinical rele-
vant antibody speciWcities without immunisation are
traced out in the following. Intact antibody molecules have
often been used to target nanoparticles, but their relatively
large size of about 12 nm, and the immunogenicity of their
Fc region, mandates use of antibody fragments rather than
intact antibody molecules.
Rodent monoclonal antibodies
The capacity to recognise and home in on a single particular
epitope requires monoclonality of the antibody, which
then can be prepared in a puriWed and standardised form
suitable for pharmaceutical application. Soon after Köhler
and Milstein (1975) presented protocols for production of
monoclonal antibodies (mAbs), development of mAbs as
drugs began; the Wrst mAb approved by the FDA for clini-
cal application being the murine monoclonal antibody
Muromonab CD3 (OrthoClone OKT3®) (Thistlethwaite
et al. 1984) in 1986; other examples include Ibritumomab
(Zevalin®) and Tositumomab (Bexxa®), both used as
therapies for non-Hodgkin’s lymphoma; currently more
than 20 FDA-approved mAb therapies exist, with
hundreds more undergoing clinical trials (Waldmann
2003). However, a considerable amount of further devel-
opment has been necessary to achieve full beneWts from
mAbs (Gavilondo and Larrick 2000). It is diYcult to
obtain human antibody responses to autologous antigens,
and immunising human donors raises ethical problems.
There was general failure to develop human hybridomas
or to immortalise human B cells by use of viruses; only in
2001 was successful generation of a human myeloma cell
line for hybridoma production reported (Karpas et al.
2001). Development therefore focussed on improving
rodent mAbs, and this was carried out in a number of
stages. Production of recombinant murine antibodies was
followed rapidly by partial humanisation of the antibod-
ies, which replaced the murine Fc region with human Fc.
A more complete humanisation was then achieved by
replacing the murine Fc framework regions with human
Fc framework regions. This sequence of development has
resulted in a mixed variety of antibodies in clinical use,
derived from each stage of this development procedure;
mAbs from each stage of the development were used to
target nanoparticles. The use of humanised antibodies will
increase in future, but mAbs from each stage of the devel-
opmental process were used to target nanoparticles. Many
investigations aimed to use the targeted nanoparticles to
deliver drugs, packing thousands of drug molecules into
the nanoparticles and attaching antibodies or scFvs to
target them. This approach has been furthest developed123
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immunoliposomes doubly targeted to transferrin receptor
and insulin receptor and bearing antisense mRNA against
the epithelial growth factor receptor (Zhang et al. 2002),
and anti-transferrin receptor scFv-immunoliposomes (Xu
et al. 2002).
Rodent recombinant monoclonal antibodies
At present, most mAbs are generated from rodents, in
which it is easy to obtain strong immune responses to
human antigens. The rodent origin of the mAbs however, in
its turn, raises problems with human immune responses to
rodent proteins after repeated application in patients. Major
problems were encountered with the clinical use of mAbs
due to strong “antiglobulin” immune responses (Isaacs
1990) to the non-human (rodent) sequences they contain
(Kabat et al. 1991). These responses reduce serum half-life,
block antibody activity, and cause allergic reactions or, in
the worst case, anaphylaxis (Stern and Herrmann 2005) and
necessitate patient preparation with corticosteroids. They
peak 8–20 days after Wrst application, limiting Wrst treat-
ment to 10 days and, due to rapid onset of a secondary
response, preventing retreatment later (Routledge et al.
1993). Such nanoparticles will be useful in biomedical
research, but since less immunogenic antibody fragments
are available they will not Wnd application in clinical diag-
nostics.
Partly humanised rodent monoclonal antibodies
In answer to the problems encountered with rodent recom-
binant mAbs, considerable eVort was invested in antibody
gene engineering. The results were Wrstly chimaeric and
later humanised antibodies. In a series of developmental
engineering steps, murine mAbs were modiWed to reduce
their immunogenicity, to increase their half-life in the body,
and to enhance their recruitment of eVector functions in the
human body. As Wrst step, recombinant chimaeric genes
were constructed, which contained exons encoding mAb
variable regions from rodents and constant regions from
humans (Boulianne et al. 1984; Morrison et al. 1984). The
resulting antibody is »65% human, reducing antigenicity
caused by the murine Fc region and thereby increasing
serum half-life. Genetically engineered immunoglobulins
are increasingly being approved for clinical use and under-
going clinical trials beyond Phase I (Stockwin and Holmes
2003; Gavilondo and Larrick 2000). An example of a chi-
maeric mAb is Rituximab (Rituxan®), an anti-CD20 used in
therapy of chronic lymphocytic leukaemia (CLL) (Nabhan
et al. 2003). Chimaeric mAbs are being superseded by
humanised rodent mAbs; so, they are unlikely to Wnd appli-
cation in diagnostic molecular imaging of humans.
Humanised antibodies
Crystallographic analysis of mAb variable (V) regions
revealed three hypervariable loops per domain; these
“complementarity determining regions, CDRs” being the
structures required to bind the epitope and these CDRs
being embedded in more conserved “framework regions”.
Residual immunogenicity is retained in chimeric mAbs,
because they contain murine V region frameworks and
CDRs. Antibody engineering technologies were therefore
used to replace the murine framework regions with human
framework regions. Such constructs minimise the non-
human contribution to the mAb to »5%, retaining only the
minimum essential rodent sequences required for epitope
recognition; these constructs are termed “humanised
mAbs”, examples include Alemtuzumab (Campath®), an
anti-CD52 (pan-lymphocyte) antibody used in the therapy
of CLL, and Trastuzumab (Herceptin®), used in the therapy
of breast cancer. The development of the Campath antibody
(Alemtuzumab) from Campath-1M (rat IgM) to Campath-
1G (rat IgG-2b) and then to Campath-1H (human IgG-1)
was reviewed by Routledge et al. (1993), discussing the
trade-oVs between maximising the antibody aYnity and the
degree of humanisation of the framework regions (i.e.,
aYnity against immunogenicity). The trade-oV is necessary
because humanised mAbs have signiWcantly lower aYnities
than the parent molecules (Carter et al. 1992; Presta et al.
1993; Riechmann et al. 1988; Hofheinz et al. 2003;
D’Amato 2003). Techniques used to raise the aYnity
include introducing mutations into the CDRs (Chotia et al.
1989), chain-shuZing, randomisation of CDRs, and site-
speciWc mutagenesis (Waldmann 2003). A fully non-immuno-
genic mAb is not attainable for all patients, because the
human Fc region is coded by diVerent alleles carrying
allotypic markers, to which antiglobulin responses can
occur (van Loghem 1986). It should be noted that humani-
sation is not predictive of the “humanness” of the mAbs,
which can only be assessed by comparing the sequence
homologies (Routledge et al. 1993).
Human antibodies
Human or humanlike mAbs can be obtained in several
ways: by transforming B cells from immune human donors
(Karpas et al. 2001), by PCR cloning and phage display
from immune human donors, by expression and selection
from synthetic phage libraries of human V regions (Winter
et al. 1994), and Wnally by immunisation of transgenic mice
bearing human germline gene segments (Mendez et al.
1997; Kellermann and Green 2002; Hudson and Souriau
2003; Bruggemann and Neuberger 1996). The mAbs bear
the Fc region with its immunogenic variability; so, these
antibodies can cause immune reactions in a small minority123
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imaging.
Antibody fragments
Targeting to tissues such as solid tumours presents the chal-
lenge of overcoming multiple barriers, as discussed below.
Antibodies are approximately 150 kDa in size and are
therefore cleared slowly from the blood pool; this leads to
signiWcant accumulation in normal organs and relatively
limited delivery to lesions such as tumours (Colcher et al.
1998). Only seldom is there a report of good penetration of
mAbs into a bulky solid tumour (Scott et al. 2005). The
relatively poor targeting eYciency of intact mAbs may fall
to zero in the case malignant cells located behind barriers,
which are not reached and therefore survive the treatment.
Use of small fragments of the antibody molecule such as
Fabs and Fvs improves penetration into target tissues: Fab’
fragments (molecular weight MW » 50 kDa; »6 nm in
size) and Fv (variable region fragments, MW » 25 kDa,
»3 nm in size) are cleared much faster from the blood than
are intact IgG molecules, and penetrate tissues much more
eVectively (Colcher et al. 1998). Earlier use of proteases to
generate mAb fragments has been replaced by molecular
cloning and expression of the variable region genes (V
region genes) of IgG, connecting genes encoding for heavy-
chain and light-chain variable regions at the DNA level by
an oligonucleotide linker. The single-chain fragments
(scFv), which are produced, cannot recruit immune eVector
functions. Intact IgG molecules have two Fv chains, but
scFvs have only a single binding site; so, their binding
aYnity is less than that of the parent molecules. The scFv
with its faster clearance and lower aYnity results in a lower
eVective dose at the target site, as compared to the divalent
IgG molecules; this must be compensated by a higher sig-
nal generation in the functional load. It is likely that scFv
generated by phage display will be used in future to steer
nanoparticles to their targets, because they can be engi-
neered to induce no immune response.
Phage display for single-chain antibody fragments
The obvious future signiWcance of the phage display tech-
nique warrants a brief description here. It allows antigens to
be targeted by scFvs without need for immunisation of a
host animal (Smith et al. 2004). The technique was Wrst
described by McCaVerty et al. (1990). Large repertoires of
heavy and light chain V regions are created as DNA
sequences ampliWed by polymerase chain reaction from
immunised humans (Cai and Garen 1995) or animals
(Chester et al. 1994). These V-chain sequences are spliced
to the gene sequence for a phage-coat protein. Expression
of the spliced DNA segments results in scFv/phage-coat
fusion proteins expressed at the bacteriophage surface. The
phage particles are secreted into the culture medium, with-
out lysis of the bacterial cell, and display at their surfaces
scFv/phage-coat fusion proteins capable of recognising and
binding an epitope of the desired antigen. Phage carrying V
genes encoding binding activities can then be selected
directly with antigen by several rounds of aYnity binding,
allowing rapid screening of large libraries of potential bind-
ing activities. The derivation of scFvs from humans results
in targeting groups of low immunogenicity, of great poten-
tial use for attachment to nanoparticles destined for clinical
use in diagnostic molecular imaging.
Entirely synthetic antibody fragments
The V region repertoires need not be derived from
immunised animals but can be created by randomised per-
mutation (Vaughn et al. 1996); in this way, the technology
has become available to generate libraries of V region
genes without immunisation, and to screen them for utility
as targeting agents directed to any desired antigen. This
bypasses immunisation strategies. No animals are needed
and production is rapid. scFvs can replace intact antibodies
in both research and clinical applications; the Wrst to enter
clinical use was MFE23, speciWc for carcino-embryonic
antigen (Chester et al. 1994). An interesting example is an
anti-VEGF scFv (Vitaliti et al. 2000; Smith et al. 2005; for
review, see Smith et al. 2004).
Oligonucleotides (aptamers)
Aptamers are small synthetic nucleic acid molecules, either
DNA or RNA, with molecular weights as low as 5–10 kDa,
which act as ligands binding to proteins (Brody and Gold
2000) or to small molecules including metabolites (Ohsawa
et al. 2008). They can be screened rapidly, eYciently, and
automatedly by the SELEX screening procedure (“system-
atic evolution of ligands by exponential enrichment”) to
select sequences optimal for binding to a particular target
(Tuerk and Gold 1990; Ellington and Szostak 1990; Tian
2002). They can identify single proteins of interest in com-
plex mixtures derived from whole cells (Morris et al. 1998;
Daniels et al. 2003), for example, recognising single pro-
teins expressed in tumour microvessels but not normal
microvessels (Blank et al. 2001). The SELEX technique
can be applied to “diYcult” targets such as large transmem-
brane molecules, generating aptamers capable of blocking
speciWc intracellular signalling pathways (Cerchia et al.
2005). They are therefore excellent tools in cancer research
and therapy (Shangguan et al. 2006) and in cardiovascular
research and therapy (Keefe and Schaub 2008). They can
bind to pathogens such as trypanosomes (Homann and
Goringer 1999; Ulrich et al. 2002; Adler et al. 2008),123
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2004), blocking their adhesion to their target cells. Their
advantages as targeting agents include their rapid and
inexpensive chemical synthesis, which results in high
homogeneity, an important characteristic for quality con-
trol. They are stable over long-term storage at ambient
room temperature. Unlike lipids, they can target speciWc
cell types, and unlike peptides their conjugation chemistry
can be simpliWed by use of hybridisation or co-synthesis
(Chu et al. 2006a). Their low molecular weights facilitate
their penetration into tissues and cells. For pharmaceutical
applications, aptamers require modiWcation to provide
resistance against nucleases and to prolong their lifetime in
the bloodstream (Brody and Gold 2000). Aptamers bound
to signal emitters, such as Xuorochromes or radionuclides,
label cancer cells selectively (Hicke et al. 2006; Chu et al.
2006a) and are capable of suppressing the proliferation of
some cancer cells (Huang et al. 2008a). They have been tar-
geted mainly to prostate cancers, but also to breast cancer,
lung cancer, and lymphomas (Shangguan et al. 2006). Con-
jugated to small molecules such as siRNAs (Chu et al.
2006a), toxins (Chu et al. 2006b), or doxorubicin (Lupold
et al. 2002), they are taken up speciWcally and mediate tar-
geted destruction of the target cells. Conjugated to nanopar-
ticles, their relatively weak binding can be compensated by
attaching many aptamers to each nanoparticle (Huang et al.
2008b). Aptamer–nanoparticle conjugates have been exten-
sively reviewed (Teply et al. 2006; Farokhzad et al. 2006b;
Ellington et al. 2007). Conjugated to nanoparticles, they
target cancer cells of diVerent types, including prostate can-
cer (Lupold et al. 2002; Farokhzad et al. 2004, 2006a;
Zhang et al. 2007; Wang et al. 2007) and breast cancer
(Huang et al. 2008a). With speciWcity for integrins, they
target tumour vasculature (SchiVelers et al. 2004), and
targeted to VEGF, they strongly inhibit endothelial cell
proliferation in vitro (Willis et al. 1998). They are ideal tar-
geting groups for nanoparticles destined use in molecular
imaging. Since they are very small, they require attachment
to the nanoparticles via linkers suYciently long to ensure
that they are not sterically hindered from contacting their
speciWc targets.
Peptides
Oligopeptides play multiple roles in nanomedicine. Some
can serve as templates for nanoparticle formation, whereas
others, especially homo-oligomers, are used as charged
molecules for formation of nanoparticles (Kish et al. 2006).
Small peptides are frequently the drug payloads incorpo-
rated into nanoparticles. Many others are used as targeting
groups, including the RGD peptide, which binds speciW-
cally to integrin (SchiVelers et al. 2004), NC-1900, an
active fragment analogue of arginine vasopressin (Xie et al.
2006), hexa-L-aspartic acid, which targets to bone (Hira-
bayashi and Fujisaki 2003), the TAT peptide for enhance-
ment of cellular internalisation (Lutz et al. 2007) and signal
peptides for nucleus and mitochondria (Hoshino et al.
2004). Oligopeptides share the advantages of aptamers
when used as targeting groups.
Lectins
Lectin-conjugated nanoparticles have found uses in
research applications (Paschkunova-Martic et al. 2005;
Arangoa et al. 2000; Ezpeleta et al. 1999). Lectin-conju-
gates, ranging in size from »12 kDa to more than 150 kDa,
penetrate blood-tissue barriers with varying eVectiveness.
Their often exquisite speciWcity and binding aYnity, rival-
ling those of the antibodies, can be used as blocking
reagents but cannot activate the eVector functions of the
immune system. Unlike antibodies, their development must
generally take place on a case-by-case system, inhibiting
the establishment of a generally applicable corpus of tech-
niques. Their major advantage over all other targeting sys-
tems, that they target oligosaccharide conWgurations, is not
absolute: clinically relevant diVerential glycosylations can
be recognised by antibodies (Pericleous et al. 2005). Many
intercellular recognition functions are lectin-mediated (for
example, the selectin recognition system, which initiates
inXammation). As intercellular communication distortions
become increasingly recognised as part of numerous patho-
physiologies, therefore, lectins may have important roles to
play in the future; it remains to be seen whether they will
Wnd a niche that cannot be occupied by antibodies.
SpeciWc ligands
Molecules expressed speciWcally at the surfaces of relevant
cells, such as endothelial cells or tumour cells, oVer a wide
choice of potential markers. Some of these underlie the
greatest market successes in recent cancer therapeutics.
Their use in molecular imaging is not so far developed, but
could be of great importance in the future. A selection of
such molecules is mentioned here; some of them highlight
possible mechanisms for routing nanoparticles across tissue
barriers and into cells. These molecules have been used to
ferry drugs into tumours, but in each case, there is a poten-
tial for attaching these molecules to nanoparticles bearing
signal-generating groups, thus adapting the molecules for
use as diagnostic targeting groups in molecular imaging.
The Wrst class of molecules are the nutrient molecules.
These require ferrying across barriers and therefore possess
speciWc receptors, which initiate transport into and across
barrier cells (such as endothelial cells) using endoytotic and
transcytotic mechanisms. This allows a drug bound to the
nutrient molecule to piggyback into and across the cell, so123
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Wrst example is albumin, the major protein and transporter
molecule of the blood, which binds as a ligand to speciWc
receptors (Vogel et al. 2001) on the surfaces of endothelial
cells and also of tumour cells (John et al. 2003; Schubert
et al. 2001; Predescu et al. 2004; Minshall et al. 2003;
Tuma and Hubbard 2003; Tiruppathi et al. 1997; Yumoto
et al. 2006). These receptors facilitate passage of albumin
out of the blood and into solid tumours and tumour cells.
Drugs bound to albumin therefore piggyback across the
endothelial cells via active transport (Chuang et al. 2002).
The uptake receptors for albumin are expressed in
increased amounts in tumours (Brown et al. 2001; Thomas
et al. 2000; Watkins et al. 2005; Infante et al. 2007). Albu-
min is an excellent targeting ligand for these reasons and is
now being attached to a variety of drugs to improve their
bio-availability and bio-compatibility. The Wrst example of
this is nab-paclitaxel (“nanoparticle albumin bound-paclit-
axel”) (Abraxane®), which consists of a nanoparticle,
approximately 150 nm diameter, with a core containing the
taxane paclitaxel and the albumin surrounding it. The albu-
min targets the drug to the solid tumour, as demonstrated in
clinical trials (Gradishar et al. 2006); the formulation was
approved for clinical use by FDA in 2005. Albumin uptake
and targeting involves mechanisms necessary for tumour
cell nutrition; therefore, it is common to many types of
tumour and is a strong candidate for molecular imaging
detection of tumours. A similar example is the use of trans-
ferrin to target drugs to tumours via receptor-mediated
mechanisms (Heidel et al. 2007; Iinuma et al. 2002),
bypassing the P-glycoprotein (Schnyder et al. 2005). In
addition to use of transferrin as ligand, the transferrin
receptor is targeted by use of anti-transferrin antibodies. A
third example is the use of the lipoprotein receptor to ferry
drugs across the blood–brain barrier. (Low density) apoli-
poprotein receptors B,E (Weisgraber 1994) are common in
the central nervous system (Pitas et al. 1987), and on endo-
thelial apical cell surfaces (Meresse et al. 1989), where they
mediate uptake of lipids into the central nervous tissue
(Ribalta et al. 2003) by endocytosis and transcytosis
(Vasile et al. 1983) and possibly participate in cell signal-
ling mechanisms (Nimpf and Schneider 2000). They are
therefore well suited for use in ferrying nanoparticles into
the brain, using lipoproteins (Kreuter 2002; Michaelis et al.
2006) or mimetic molecules (Croy et al. 2004) as Trojan
horses. Folate is a fourth example. Tumour cells frequently
express high levels of folate receptor, which has been
shown to facilitate entry of folate-conjugated toxins and
prodrugs into the tumour cells. Folate has been used to tar-
get nanoparticles into tumours (Rossin et al. 2005; Gabizon
et al. 2003; Shmeeda et al. 2006; Shiokawa et al. 2005). A
Wnal example is the mannose receptor; these are expressed
exclusively on antigen-presented cells; mannose has been
used to target nanoparticles to macrophages and dendritic
cells (Hattori et al. 2006). A second class of speciWc mole-
cules for targeting are the growth factor receptors, which
are often expressed in especially high concentrations at the
surfaces of tumour cells. One example is the family of
transmembrane receptor tyrosine kinases, such as the recep-
tor for epithelial growth factor (erbB/HER/EGF-R) (Lidke
et al. 2004), and another is the family of receptors for the
vascular endothelial growth factor (VEGF-R) (Willis et al.
1998). However, at present, the ligands EGF and VEGF are
not are not utilised to target their receptors; instead, these
receptors are targeted by use of speciWc antibodies. A third
class of speciWc molecules for targeting are the cell surface
adhesion molecules, which also are often expressed in espe-
cially high concentrations at the surfaces of tumour cells.
EpCam (CD326), one of the Wrst tumour-associated anti-
gens identiWed (Baeuerle and Gires 2007), is overexpressed
in a wide range of tumours including breast carcinomas
(Osta et al. 2004), urothelial carcinomas (Brunner et al.
2008), pancreatic carcinomas (Fong et al. 2008), and hepa-
tocellular carcinomas (Yamashita et al. 2007). This list rep-
resents only a small selection amongst the many lesion-
speciWc ligand–receptor pairs that can be considered for use
as targeting systems in diagnostic molecular imaging.
The signalling groups
The selection of signalling groups depends on the application
for which the molecular imaging is planned. In some cases,
damage to ionising radiation must be avoided; in other cases,
it can be accepted. For some purposes, an inexpensive
modality is appropriate; for other purposes, an expensive
modality must be used. Financial and ethical considerations
must be integrated with the technical considerations.
Strongly ionising signalling groups are acceptable in
monitoring these therapies in which strong ionisation is part
of the therapy itself (for example, in brachytherapy, in anti-
body-targeted and aptamer-targeted radionuclear thera-
pies). PET imaging is therefore a staple of therapies in
nuclear medicine. The scintigraphic imaging presently used
to detect metastases in oncology is also being supplemented
by scintigraphic molecular imaging. Ionising radiation is
required for detailed imaging of calciWed tissues; other pos-
sible applications are considered below.
Amongst the non-ionising signalling media, photons in
the visible spectrum are the most easily generated and the
least expensive. For surface and near-surface imaging, the
near-infrared spectrum is ideal and is well represented by
quantum dots and by organic Xuorochromes. For studies
involving small animals and tissue cultures in research, the
entire visible spectrum and the near-infrared spectrum are
used in combination with light microscopy of several vari-
ous types, and with optical imaging by use of cameras. It is123
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diVerent colours of quantum dots and thus to perform mul-
tispectral imaging, allowing tracking of several diVerent
antigens simultaneously. Unfortunately, quantum dots Wnd
only limited applications in patient care, because they con-
tain semiconductor cores fabricated from highly toxic ele-
ments. They have been used to locate sentinel nodes in
oncology. However, they are a varied group of nanoparti-
cles typically based on toxic cores, which may be exposed
by oxidative, photolytic, and mechanical instabilities
(Hardman 2006; Chan et al. 2005). Their suitability as
vehicles for targeted drug delivery is debatable, because
any disruption of the outer shell (in which the drug must be
loaded) may expose the toxic core. An alternative to quan-
tum dots are the nanoclusters of silver and gold, which also
have exciton properties and emit pure monochromatic light;
the gold nanoclusters provide a non-toxic source of strong
signalling for Xuorescence microscopy and optical imaging.
The deep internal organs of large animals and humans
can most expeditiously and inexpensively be imaged by use
of ultrasound molecular imaging. MRI by use of USPIOs or
SPIOs presently provides tracking of lymph nodes in
oncology, and MRI by use of other nanoparticle contrast
media is being developed for future use. The signalling
groups available for MRI include not only gadolinium but
also Xuorine and europium.
Screening for latent illness is one of the future possibili-
ties of molecular imaging. The nanoparticles required for
this will be costly; so, such screening will only be Wnan-
cially viable for major killer diseases. The ethical, Wnancial,
and technical conundrums become most visible in this con-
nection. The choice of imaging modality is here largely
determined by expense and availability, which renders MRI
an unlikely selection. PET is likewise hampered by the
extensive infrastructure required and by the application of
strongly ionising radiation. Ultrasound imaging is a likely
candidate, with the proviso that the microbubbles must be
shown to penetrate to biomarkers hidden deep within early
lesions. For near-surface structures such as the peripheral
arteries and veins, which are of considerable interest for
screening for atherosclerosis, near-infrared optical imaging
and photoacoustic imaging both provide strong candidates.
Finally, direct X-ray imaging oVers an inexpensive modality
with minimal ionisation damage, justiWed if it is shown to
detect early stages of major killer diseases and to impact
morbidity or mortality rates. Screening applications of
molecular imaging are at present hopes for the future and
have not been realised in practise.
The linkers
The high aYnity of the targeted nanoparticle for its target
does not depend solely on the targeting group, but on the
entire particle, including the linker and the linked particle.
The targeting groups must retain or acquire their functional
conformation (e.g. aptamers), and must present their bind-
ing site in an orientation, which allows binding and at a dis-
tance from the bulk of the particle so that steric hindrance
does not prevent binding. These requirements for spatial
positioning of each targeting group mandate selection of a
linker of appropriate size, shape, and stiVness. In addition,
the electronic conWguration at the binding site (overall
charge, charge distribution at the binding site) must facili-
tate binding, and this requires that the chemistry of the
linker be chosen to conWgure charge accurately around the
binding site. Selection of a suitable linker is an intricate and
time-consuming task, even for attachment of a targeting
group to a small molecule. It is a task likely to require yet
more attention for the attachment of a targeting group to a
nanoparticle, which is typically more than 10,000 times
more massive than a small drug molecule. At present, many
workers attach the targeting groups to nanoparticles by use
of PEG as linker (SchiVelers et al. 2004), thus using the
PEG both as linker and as an immune-evasion coating.
Alternatively, avidin–biotin non-covalent linkages are
employed (Schnyder et al. 2005; Wu et al. 2003; Chan et al.
2005), with their intrinsic advantage of modularity, allow-
ing any biotinylated targeting group to be easily mounted
on an avidin-bearing nanoparticle. Streptavidin, used for
targeted delivery of therapeutics in whole animals (Zhang
and Pardridge 2001; Schnyder et al. 2005), is a tetramer
(Chu et al. 2006a), binding four biotins and thus allowing
mixing of internalising and targeting moieties (Chu et al.
2006a; Ellington et al. 2007). Finally, there may be an
important role in the future for use of nucleotide linkers to
connect targeting groups with nanoparticles. Both DNA
and RNA oligonucleotides are being actively studied as a
means to build arrays of nanoparticles in materials and sen-
sor sciences (Letsinger et al. 2001); these technologies can
be applied by straight transfer to linking targeting groups to
nanoparticles. Oligonucleotide linkages provide in princi-
ple the possibility of pre-programming functions into the
linkage between targeting group and nanoparticle.
Tissue barriers
The shortest path to tissues in most internal organs is via
the blood, generally after intravenous injection. This short
path is nonetheless complex: the nanoparticles’ target may
lie behind several blood-tissue barriers, including endothe-
lial cells, subendothelial basement membranes (spatial and
charge Wlters), micrometres of extracellular matrix (also a
Wlter) in which sheetlike Wbroblast processes and collagen
bundles form physical obstacles, and Wnally the subepithe-
lial basement membrane (Fig. 6). These barriers are
reduced in lesions, allowing wash-in of the nanoparticles,123
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Ideally, all the targeted nanoparticles will accumulate at the
targets, but this 100% targeting eYciency is not reached for
several reasons; some nanoparticles are sequestered into the
reticulo-endothelial system and others into the liver. Fur-
thermore, those nanoparticles, which remain in the blood,
generate a background signal, which reduces the contrast
available for detection of signal from the target sites.
Reduction of the background signal can be achieved by
PEGylation, reducing uptake into the reticulo-endothelial
system. It can be achieved by shortening the halXife of the
nanoparticles in the blood. The background signal can be
reduced dramatically by arranging for signal generation to
occur only when switched on at arrival in the target site:
“molecular beacons” (Massoud and Gambhir 2003).
Viruses, natural nanoparticles, do overcome such barri-
ers and reach multiply protected targets: the polio virus
starts from the gut lumen to reach targets in the central
nervous system. Viruses, however, bear enzymes to modify
their environment, which until now has not been achieved
with artiWcial nanoparticles.
Toxicity and pharmacokinetics
Nanoparticle interactions with living tissues bring novel
risks. Nanoparticles have immense surface areas for chemi-
cal reaction: 1 g of 30 nm diameter nanoparticles contains a
particle surface area > 200 m2, exceeding the combined
surface areas of one hundred men (each with surface
area » 1.5 m2). Obvious risks are therefore potentiated
(Brown et al. 2001; Donaldson et al. 2006; Oberdörster
et al. 2005b). Some nanoparticles, such as quantum dots,
are constructed from highly toxic materials and their dan-
gers are evident. However, unexpected toxicities have been
documented for materials, which are not normally consid-
ered toxic, such as silver, but which become toxic when
presented in nanoparticle form. Furthermore, extensive epi-
demiological studies have shown that materials, which are
toxic, such as particulate materials in industrial smokes and
in smog (Brown et al. 2001; Clancy et al. 2002; Gilmour
et al. 2004; Dailey et al. 2006; Lam et al. 2004; Medina
et al. 2007; Pope 2001; Peters and Pope 2002; Salvi et al.
2000; Steerenberg et al. 1998; Yang et al. 1997), are decidedly
more toxic if they are present as nanoparticles rather than as
microparticles (Brook et al. 2004; Donaldson et al. 2005;
Gilmour et al. 2004; Yamawaki and Iwai 2006). The use of
(undeclared) nanoparticle therapeutics in medicine has so
far not led to signiWcant health risks. The FDA and the
EMEA do not at present detect nanoparticle-speciWc risks.
However, there are several grounds for caution. In princi-
ple, any active agents within the nanoparticle should be
steered to the target site without adding risk. The ideal
drug-bearing nanoparticle will release its drug only at the
required site of action; it will release all its drug there at a
speciWed rate, and the nanoparticle will then dissolve into
entirely non-toxic components. The present state of the art
does not attain these goals, and the nanoparticles release
their loads too early and non-speciWcally, or have a pharma-
cokinetic of their own, which must be checked for toxicity.
The multiple pharmacokinetic pathways characterising
nanoparticles composed of several components must be
checked, in particular ensuring that one type of clearance is
not interfering with another. Some nanoparticle breakdown
products, such as gadolinium chelates, have well-studied
pharmacokinetics involving toxic risk to a very small num-
ber patients with kidney diseases (Broome et al. 2007; Kuo
et al. 2007; Rofsky et al. 2008): this toxicity is not nanopar-
ticle-speciWc, but nanoparticles containing these chelates
may cause such toxicity if they are administered. Nanopar-
ticles are as risky as their components, in addition to any
further risks due to their nanoscale size. Concerning the
Fig. 6 Electron micrograph [reproduced from Wieser et al. (2004),
with permission], showing the morphological barriers hindering a
nanoparticle in the blood (inside red ring) from reaching its target in
the cytoplasm of an epithelial cell. The prostate carcinoma tissue
shown here has an area of the tumour in which the morphological rela-
tionships resemble those of non-cancerous tissue, and in which the sys-
tem of barriers is essentially complete: this is a region of the tumour in
which any cancer cells present will be diYcult for targeted nanoparti-
cles to access. The nanoparticle, in the capillary lumen, must cross the
endothelial wall (EC endothelial cell), then the subendothelial base-
ment membrane (short arrows), any Wbroblast sheetlike processes (*)
in close proximity to the blood vessel, extracellular matrix containing
collagen Wbres (long arrows), the subepithelial basement membrane
(arrowheads) and Wnally cross the epithelial cell membrane to enter the
cytoplasm of the epithelial cell (EP). The presence of caveolae in the
wall of the endothelial cell (to the right side of the nanoparticle) al-
ready represents a partial failure of the barriers in this tissue. Calibra-
tion bar 1.0 m123
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interactions might occur between artiWcally introduced
nanoparticles and the numerous natural nanoparticles,
which are essential for the vital functions of cells and
organs (Oberdörster et al. 2005a, b). Most of the intracellu-
lar machinery consists of nanoparticles (ribosomes, protea-
somes, intracellular vesicles, ion channels, various
membrane transporters, the nucleotides DNA and RNA in
two of their three dimensions, the cytoskeletal Wbres in two
of their three dimensions, and many others); many extracel-
lular components also have nano-dimensions. The poten-
tially highly reactive nanoparticles may enter as yet
unexplored interactions with biological nanoscale struc-
tures. There are then certain forms of toxicity that may be
associated especially with targeted nanoparticles; for exam-
ple, if an antibody as targeting group steers the particles
into a healthy tissue, because that tissue presents epitopes
cross-reacting with the target epitopes of the pathological
tissues; the result of such cross-steering could be a heavy
eVective dose to a healthy tissue in addition to the therapeu-
tic dose to the diseased tissue, and could thus cause particu-
larly severe side-eVects. In addition to this, it has been
shown that eVective targeting reduces, and ineVective tar-
geting raises, exposure in the liver (Iinuma et al. 2002). In
radionuclide-based imaging, there is in addition a need to
reduce the radio dose to the kidney (Forster et al. 2006).
The targeting group may also activate the immune
response, as has been documented for some aptamers (Rey-
nolds et al. 2006) and proteins (Heidel et al. 2007). The
linker may also elicit an immune response, for example
streptavidin (Breitz et al. 2000), though it is possible to
minimise this (Meyer et al. 2001). In view of the nanostruc-
ture-speciWc potential toxicities and enhanced toxicities, it
is necessary to develop specially adapted hierarchical
standardised toxicity testing procedures for nanomedicine.
Nanotoxicology is emerging as a new branch of toxicology,
focussing on novel undesirable phenomena associated with
nanoparticles (Donaldson et al. 2004; Service 2004; Seaton
and Donaldson 2005). Tiered testing regimes taking
account of properties speciWc to nanoparticles are being
developed. These include testing and understanding poten-
tially toxic eVects of particles size (Jani et al. 1990), size
distribution, agglomeration state, shape, crystal structure,
e.g., single-wall carbon nanotubes induce pulmonary inter-
stitial Wbroses whereas carbon black (amorphous carbon
nanostructures) do not (Kipen and Laskin 2005; Schvedova
et al. 2003; Lam et al. 2004; Donaldson et al. 2006), chemi-
cal composition (Dailey et al. 2006), surface area, surface
chemistry, surface charge, and porosity. Hierarchical toxi-
cological testing protocols under development will assay
these combined risks (Oberdörster et al. 2005b). In this
way, the multidisciplinary nature of nanotoxicology reXects
that of nanotechnology itself (Oberdörster et al. 2005a, b).
Perspectives
Nanomedicine applies the remarkable properties of nano-
sized materials to healthcare, increasing diagnostic sensitivity
and speciWcity for speciWc disease-related processes and
molecules. This includes remarkable enhancements in the
clinical laboratory (e.g., Lee et al. 2007) and in histopathology
(e.g., Xing et al. 2007); amongst this vast new Weld, this
review has focussed on imaging in living organisms, which
oVers the potential to detect diseases at an early stage, gain
new insights in the pathogenesis of certain diseases, monitor
therapeutic response, and develop individualised therapies
for certain diseases. Aims include identifying apparently
healthy people hiding threatening lesions (Boisseau et al.
2006). In molecular imaging, localised clusters of cells bear-
ing molecular insignia of disease are good targets, imaging
with high contrast, because the surrounding tissue lacks
such insignia. An early-stage tumour, prior to the angiogenic
switch (Folkman 2001) and less than 2 mm diameter, con-
tains more than two million cells, so is well within the detec-
tion and resolution capabilities of nanoparticle-based MRI.
Nanoparticle-based molecular imaging therefore oVers the
potential of identifying malignancies at stages much earlier
than those detectable today. Similar considerations apply to
atherosclerotic lesions (Hellings et al. 2007). Any disease in
which small disseminated lesions have diagnostic signiW-
cance is a candidate for diagnostic molecular imaging; this
includes infections, endometrioses, multiple sclerosis, and
cancer (Weissleder and Pittet 2008). Diagnostic molecular
imaging is a hot research Weld in which numerous workers
are following diVerent leads; so, a short review cannot do
justice to the multiplicity of excellent reports; the Weld was
reviewed frequently during the last 10 years (Massoud and
Gambhir 2003; Moghimi et al. 2001; JaVer and Weissleder
2005; Brindle 2003; Weissleder and Mahmood 2001; Wick-
line and Lanza 2003; Pomper 2005). Research highlights
include imaging of angiogenesis with integrin 5ß3 as target
or of thrombi with Wbrin as target (Wickline and Lanza
2003), and of angiogenesis with matrix metalloproteases
imaged by probes that can be activated (Massoud and
Gambhir 2003). Tumour cell imaging was carried out in
breast cancer by use of Her2/neu (Herceptin®) by both
photoacoustic imaging (Copland et al. 2004) and MRI (Lee
et al. 2007). A major focus has been the imaging of gene
expression (Massoud and Gambhir 2003; Weissleder and
Mahmood 2001). Stem cell tracking has been found to suc-
ceed better by use of MPIOs than USPIOs or PIOs, as
described earlier. Further aims include not just the diagnosis
but also the staging of established disease, and provision of
surrogates for drug testing. A long-term aim is to combine
molecular imaging with therapy, with drug delivery:
“theranostics” (Boisseau et al. 2006), as a major step
towards personalised medicine.123
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unite histochemistry and molecular imaging, then moved
on to consider novel aspects arising from the creation of
what are in eVect histochemical stains designed for use in
clinical procedures to diagnose illnesses in patients. For the
histochemist, much of the terrain is familiar, though the
replacement of the microscope as imaging device requires
an adjustment of thought. This is well worth while. In the
newly emerging Welds of molecular imaging diagnostics
and theranostics, the histologist has considerable expertise
to oVer, without which much will need to be developed by
trial and error, which could be rationally designed much
more quickly and eVectively if the histochemist plays his
role. This impinges on the design of the new nanoparticu-
late contrast agents. Indeed, nanomedicine is essentially
multidisciplinary. A wide range of chemical and physico-
chemical competencies is required to design, synthesise,
and analyse nanoparticles. The identiWcation of targets in
numerous diseases, expression of those targets, screening
for speciWc targeting groups, and validating those selected
requires skills in genetics, bio-informatics, chemistry,
molecular and cell biology, screening procedures, and
pathology. Clinical aspects require input from radiologists,
nuclear physicians, oncologists, pathologists, as well as
anatomists, histologists, and physiologists. Pharmacologi-
cal and logistical aspects require input from the pharmaceu-
tical sciences and industries. Selection of diseases to
address requires guidance from health-insurance experts,
actuaries, and health-care managers. Last but not least,
important ethico-legal issues require consideration. It is
evident that no one person can master this gamut of trades,
but a signiWcant minority of those involved in DMI must
speak an adequate range of the specialist languages
involved. At this interface between medicine, biology, and
materials science, those who will make it happen require
training considerably broader-based than what traditional
programs foresee.
This review closes with a glance at the “industrial”
issues of logistics and regulation. As molecular imaging
moves forward into clinical applications, the numerous
proofs of principle that have been achieved must be con-
verted into pharmaceutical realities, bringing three types
of challenge unfamiliar in the laboratory setting. Firstly,
nanoparticle synthesis must be upscaled, standardised, and
streamlined. Nanomedicine in Europe will require annual
production of tons of nanoparticles. Consider a person
containing 3 ml target tissue, then if MRI requires 1 mg/ml
of gadolinium chelate in the target(s), and this in the form
of 4,000 gadolinium ions per 30 nm nanoparticle, then
about 1 g of nanoparticles with 10% targeting eYciency
will be required for imaging. Thus, 400 million Europeans
screened annually would require »400 tons. Upscaleable
syntheses are obviously essential. Physicochemical
methods used to synthesise nanoparticles, such as emulsiW-
cation or co-acervation, involve numerous parameters
diYcult to regulate, including local reagent concentrations,
local pH and temperature, and Xow rates. Intrinsic to such
syntheses are signiWcant variations amongst the end-prod-
ucts; we and others (Vogel et al. 2002) found signiWcant
variability in nanoparticle size dispersity and gadolinium
loading ratios. The twin aims of upscaling and nanoparti-
cle standardisation represent signiWcant challenges to
chemistry in bringing nanomedicine to full fruition.
Streamlining is required primarily to trim the number of
targeting groups per particle; for some nanoparticles, the
cost of targeting is hundred-fold more expensive than the
nanoparticle itself.
Following successful upscaling, there will be regulatory
hurdles facing nanoparticles for molecular imaging in clini-
cal application. As evidence for the proximity of clinical
applications, the FDA has established a Nanoparticle Task
Force to examine the regulatory issues associated with
nanomedicine (http://www.fda.gov/nanotechnology/task-
force/report2007.html). The use of nanoparticles for thera-
peutic applications is further advanced than for diagnostics,
and the FDA has slightly eased the regulatory background
for diagnostics. DiVerent forms of iron oxide nanoparticles
for passive targeting are available for clinical use (Resovist,
Feridex/Endorem, Gastromark/Lumirem). Several groups
have Phase I/II trials of lymph node diagnostics to stage
carcinomas, including breast, prostate, kidney, testis,
bladder, and penis. It seems likely that the pre-operative
sentinel node test will in future be carried out by use of
non-ionising imaging, probably optical imaging. There is
signiWcant funding for translational diagnostic molecular
imaging research in the USA, China, Japan, and the Euro-
pean Union. A cursory search of the Internet reveals more
than 20 Molecular Imaging Facilities at universities and
research institutes across the USA, and at least one or two
in each of the developed countries; frequently, an industry
partner is closely associated with such facilities, notably
Siemens, General Electric, and Philips, and there are active
research programs at Bracco and Guerbet, the major manu-
facturers of contrast agents.
The safety aspects of molecular imaging have been in
the public eye for some time, and although there has been
no cause for anxiety until now, the perception of nanotech-
nology is likely to be ambivalent for some time to come.
The continued focus on this aspect is reXected not only in
attention by the mass media but also by requirements
placed on project leaders to demonstrate that they have
considered any potential toxicities of the agents they are
developing. So long as this alert environment is maintained
it is likely that any untoward reactions towards diagnostic
molecular imaging reagents will be detected and reported
with minimal delay.123
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Molecular imaging by use of nanoparticles, and its major
daughter, diagnostic molecular imaging, is exploring a
wide range of diVerent nanoparticle formulations and appli-
cations. When high-quality biomarkers for early disease
become available, the nanoparticles required for realisation
of diagnostic molecular imaging on a wide front will be
available. The present need is to develop cost-eYcient
nanoparticles with acceptable targeting eYciencies, favour-
able pharmacokinetics, and a good safety proWle. The Wnal
point to consider is the question of realistic timeframes.
The challenges in developing nanoparticles for molecular
imaging will not be overcome within short timelines. The
question of nanoparticle aggregation consequent to storage
and reconstitution in the clinical setting requires to be
addressed for multitasking nanoparticles. The convincing
demonstration of non-toxicity in long-term applications
and in the long-term after short-term applications will
require periods of years subsequent to successful clinical
trials. Unfamiliar types of risk must be identiWed and dealt
with (for example, problems with false targeting). There
are both legal and Wnancial aspects to face before taking
nanoparticulate agents to market, and in the marketplace
these agents will be in competition with alternative technol-
ogies aimed at solving the same problems. Under these
circumstances, the development of nanoparticles for
clinical applications must be viewed as a matter for the long
haul, with timelines counted in 5-year intervals. It would be
surprising to see clinical applications before 2015, though
this wait will be well worthwhile; histologists by proVering
their skills can help to make this wait shorter.
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